1
|
Vengrzhinovskaya OI, Bondarenko IZ, Shatskaya OA, Nikankina LV, Kalashnikov VY, Shestakova MV, Mokrysheva NG. Adipokines and the cardiorespiratory system in young patients with type 1 diabetes mellitus. TERAPEVT ARKH 2022; 94:1143-1148. [DOI: 10.26442/00403660.2022.10.201889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Indexed: 11/23/2022]
Abstract
Early screening of complications of diabetes mellitus (DM) is one of the priorities for public health. Most patients with type 1 diabetes mellitus (T1DM) are patients of working age. New strategies for the primary prevention of cardiovascular disease (CVD) are needed to prevent their early disability.
Aim. To assess the predictive value of adipokines in relation to a personalized approach to the need for an in-depth examination of young patients with T1DM.
Materials and methods. The study included 98 patients without CVD: 70 patients with T1DM (mean age 26.48.1 years) and 28 patients without DM (mean age 279 years). All patients underwent a general clinical examination, the levels of adipokines were determined, ergospirometry, echocardiography, and bioimpedancemetry were performed.
Results. Changes in the cardiorespiratory system in patients with T1DM were revealed, in comparison with persons without T1DM: anaerobic threshold was reached faster (p=0.001), maximum oxygen consumption was lower (p=0.048), metabolic equivalent was reduced (p=0.0001). Signs of myocardial remodeling were found in the T1DM group: there was an increase in the relative wall thickness (p=0.001), the posterior wall of the left ventricle (p=0.001), myocardial mass index (p=0.049), in comparison with persons without T1DM. Changes in the adipokines system were revealed: higher levels of resistin (p=0.002) and visfatin (p=0.001), lower level of adiponectin (p=0.040) in T1DM. A positive correlation was found between posterior wall of the left ventricle and visfatin (p=0.014) and a negative relationship between adiponectin and relative wall thickness (p=0.018) in T1DM.
Conclusion. In T1DM, even at a young age, there are multifactorial changes in the heart, which can be detected even at the preclinical stage. The data obtained can be used to identify groups of patients at high risk of developing dangerous CVD in T1DM, which can form the basis for determining the timing of the start of preventive therapy.
Collapse
|
2
|
Jang AY, Scherer PE, Kim JY, Lim S, Koh KK. Adiponectin and cardiometabolic trait and mortality: where do we go? Cardiovasc Res 2021; 118:2074-2084. [PMID: 34117867 DOI: 10.1093/cvr/cvab199] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Accepted: 06/11/2021] [Indexed: 12/19/2022] Open
Abstract
Adiponectin is an adipocyte-derived cytokine known for its cardioprotective effects in preclinical studies. Early epidemiologic studies replicated these findings and drew great interest. Subsequent large-scale prospective cohorts, however, showed that adiponectin levels seemed not to relate to incident coronary artery disease (CAD). Even more surprisingly, a paradoxical increase of all-cause and cardiovascular (CV) mortality with increased adiponectin levels was reported. The adiponectin-mortality paradox has been explained by some groups asserting that adiponectin secretion is promoted by elevated natriuretic peptides (NP). Other groups have proposed that adiponectin is elevated due to adiponectin resistance in subjects with metabolic syndrome or heart failure (HF). However, there is no unifying theory that can clearly explain this paradox. In patients with HF with reduced ejection fraction (HFrEF), stretched cardiomyocytes secrete NPs, which further promote release of adiponectin from adipose tissue, leading to adiponectin resistance. On the other hand, adiponectin biology may differ in patients with heart failure with preserved ejection fraction (HFpEF), which constitutes 50% of all of HF. Most HFpEF patients are obese, which exerts inflammation and myocardial stiffness, that is likely to prevent myocardial stretch and subsequent NP release. This segment of the patient population may display a different adiponectin biology from its HFrEF counterpart. Dissecting the adiponectin-mortality relation in terms of different HF subtypes may help to comprehensively understand this paradox. Mendelian Randomization (MR) analyses claimed that adiponectin levels are not causally related to CAD or metabolic syndrome. Results from MR studies, however, should be interpreted with great caution because the underlying history of CAD or CHF were not taken into account in these analyses, an issue that may substantially confound the results. Here, we discuss many aspects of adiponectin; cardiometabolic traits, therapeutic interventions, and the ongoing debate about the adiponectin paradox, which were recently described in basic, epidemiologic, and clinical studies.
Collapse
Affiliation(s)
- Albert Youngwoo Jang
- Division of Cardiovascular Disease, Gachon University Gil Hospital, Incheon, Korea, Gachon Cardiovascular Research Institute, Incheon, Korea
| | - Philipp E Scherer
- Touchstone Diabetes Center, Departments of Internal Medicine and Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, ., Dallas, TX, 75390-8549, USA
| | - Jang Young Kim
- Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea
| | - Soo Lim
- Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, Korea
| | - Kwang Kon Koh
- Division of Cardiovascular Disease, Gachon University Gil Hospital, Incheon, Korea, Gachon Cardiovascular Research Institute, Incheon, Korea
| |
Collapse
|
3
|
Lakshmanan S, Jankowich M, Wu WC, Abbasi S, Morrison AR, Choudhary G. Association of plasma adiponectin with pulmonary hypertension, mortality and heart failure in African Americans: Jackson Heart Study. Pulm Circ 2020; 10:2045894020961242. [PMID: 33240486 PMCID: PMC7675872 DOI: 10.1177/2045894020961242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Accepted: 09/02/2020] [Indexed: 12/02/2022] Open
Abstract
Background Adiponectin is a polypeptide hormone related to obesity, and a known
modulator of pulmonary vascular remodeling. Association between plasma
adiponectin levels and pulmonary hypertension (PH) has not been studied in
African Americans (AAs) who are disproportionately affected by obesity. The
relationship between adiponectin and heart failure (HF) and mortality,
outcomes associated with PH, is unclear. Methods We performed cross-sectional and longitudinal analysis to examine if there is
an association between plasma adiponectin and PH and associated clinical
outcomes, in participants of Jackson Heart Study (JHS). JHS is a prospective
observational cohort study of heart disease in AAs from Jackson,
Mississippi. Results Of the 3161 participants included in the study, mean age (SD) was 56.38
(12.61) years, 1028 were men (32.5%), and mean (SD) BMI was 31.42 (7.05)
kg/m2. Median (IQR) adiponectin was 4516.82 (2799.32–7065.85)
ng/mL. After adjusting for potential confounders including BMI, higher
adiponectin levels were associated with increased odds of PH (adjusted odds
ratio per log increment in adiponectin, (1.81; 95% CI, 1.41–2.32). High
adiponectin levels were also associated with associated HF admissions
(adjusted hazard ratio [HR] per log increment in adiponectin, 1.63, 95% CI,
1.24–2.14) and mortality (adjusted HR per log increment in adiponectin,
1.20; 95% CI 1.02–1.41). Conclusions Elevated plasma adiponectin levels are associated with PH, HF admissions and
mortality risk in AAs. High adiponectin levels may help identify an at-risk
population that could be evaluated for targeted prevention and management
strategies in future studies
Collapse
Affiliation(s)
- Suvasini Lakshmanan
- Division of Cardiology, Providence VA Medical Center, Alpert Medical School of Brown University, Providence, RI, USA
| | - Matthew Jankowich
- Division of Pulmonary, Critical Care and Sleep Medicine, Providence VA Medical Center and Alpert Medical School of Brown University, Providence, RI, USA
| | - Wen-Chih Wu
- Division of Cardiology, Providence VA Medical Center, Alpert Medical School of Brown University, Providence, RI, USA
| | - Siddique Abbasi
- Division of Cardiology, Providence VA Medical Center, Alpert Medical School of Brown University, Providence, RI, USA
| | - Alan R Morrison
- Division of Cardiology, Providence VA Medical Center, Alpert Medical School of Brown University, Providence, RI, USA
| | - Gaurav Choudhary
- Division of Cardiology, Providence VA Medical Center, Alpert Medical School of Brown University, Providence, RI, USA
| |
Collapse
|
4
|
Gunturiz Albarracín ML, Forero Torres AY. Adiponectin and Leptin Adipocytokines in Metabolic Syndrome: What Is Its Importance? DUBAI DIABETES AND ENDOCRINOLOGY JOURNAL 2020. [DOI: 10.1159/000510521] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The global obesity epidemic has motivated a large number of investigations related to adipose tissue. Within the advances in this area, a variety of factors secreted by adipose tissue and with regulatory activity on caloric intake, energy expenditure, reproduction, locomotor activity, glycidic and lipid metabolism, immune response, and bone physiology have been described. Among these adipocyte hormones, collectively called “adipokines” or “adipocytokines,” leptin (LEP) and adiponectin are addressed in this review. The regulation of adipocytokines is altered in diseases such as obesity, atherosclerosis, type 2 diabetes mellitus, and metabolic syndrome (MS) due to the increase in the mass of white adipose tissue. LEP and adiponectin have a broad spectrum of functions in regulating metabolism and are an important link between obesity and MS. Because these adipocytokines have opposite effects on subclinical inflammation and insulin resistance, it has been suggested that the combined use of these 2 adipocytokines may work as a better biomarker in the diagnosis of MS than using them individually. In this review, we address the characteristics and main functions of adipocytokines derived from adipose tissue such as adiponectin and LEP, which in the Colombian context could give good guidance for the management of MS, especially in populations of children and adolescents.
Collapse
|
5
|
Rallidis LS, Katsimardos A, Kosmas N, Rallidi T, Kountouri A. Prognostic value of adiponectin in patients with stable coronary artery disease in the era of statins. Eur J Intern Med 2020; 79:118-119. [PMID: 32359977 DOI: 10.1016/j.ejim.2020.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2020] [Accepted: 04/03/2020] [Indexed: 11/28/2022]
Affiliation(s)
- Loukianos S Rallidis
- Second Department of Cardiology, University General Hospital, "Attikon", 1 Rimini Street, Chaidari 12462, Athens, Greece.
| | - Andreas Katsimardos
- Second Department of Cardiology, University General Hospital, "Attikon", 1 Rimini Street, Chaidari 12462, Athens, Greece
| | - Nikolaos Kosmas
- Second Department of Cardiology, University General Hospital, "Attikon", 1 Rimini Street, Chaidari 12462, Athens, Greece
| | | | | |
Collapse
|
6
|
Kita S, Maeda N, Shimomura I. Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome. J Clin Invest 2020; 129:4041-4049. [PMID: 31483293 DOI: 10.1172/jci129193] [Citation(s) in RCA: 151] [Impact Index Per Article: 37.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Adipose tissue plays important roles in regulating whole-body energy metabolism through its storage function in white adipocytes and its dissipating function in brown and beige adipocytes. Adipose tissue also produces a variety of secreted factors called adipocytokines, including leptin and adiponectin. Furthermore, recent studies have suggested the important roles of extracellular vesicles of endosomal origin termed exosomes, which are secreted from adipocytes and other cells in adipose tissue and influence whole-body glucose and lipid metabolism. Adiponectin is known to be a pleiotropic organ-protective protein that is exclusively produced by adipocytes and decreased in obesity. Adiponectin accumulates in tissues such as heart, muscle, and vascular endothelium through binding with T-cadherin, a glycosylphosphatidylinositol-anchored (GPI-anchored) cadherin. Recently, adiponectin was found to enhance exosome biogenesis and secretion, leading to a decrease in cellular ceramides, excess of which is known to cause insulin resistance and cardiovascular disease phenotypes. These findings support the hypothesis that adipose tissue metabolism systemically regulates exosome production and whole-body metabolism through exosomes. This review focuses on intra-adipose and interorgan communication by exosomes, adiponectin-stimulated exosome production, and their dysregulation in metabolic diseases.
Collapse
Affiliation(s)
- Shunbun Kita
- Department of Metabolic Medicine.,Department of Adipose Management, and
| | - Norikazu Maeda
- Department of Metabolic Medicine.,Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, Osaka, Japan
| | | |
Collapse
|
7
|
Wong YK, Cheung CYY, Tang CS, Au KW, Hai JSH, Lee CH, Lau KK, Cheung BMY, Sham PC, Xu A, Lam KSL, Tse HF. Age-Biomarkers-Clinical Risk Factors for Prediction of Cardiovascular Events in Patients With Coronary Artery Disease. Arterioscler Thromb Vasc Biol 2019; 38:2519-2527. [PMID: 30354221 DOI: 10.1161/atvbaha.118.311726] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Objective- In patients with stable coronary artery disease, conventional risk factors provide limited incremental predictive value for cardiovascular events. We sought to investigate whether a panel of cardiometabolic biomarkers alone or combined with conventional risk factors would exhibit incremental value in the prediction of cardiovascular events. Approach and Results- In the discovery cohort, we measured serum adiponectin, A-FABP (adipocyte fatty acid-binding protein), lipocalin-2, FGF (fibroblast growth factor)-19 and 21, plasminogen activator inhibitor-1, and retinol-binding protein-4 in 1166 Chinese coronary artery disease patients. After a median follow-up of 35 months, 170 patients developed new-onset major adverse cardiovascular events (MACE). In the model with age ≥65 years and conventional risk factors, area under the curve for predicting MACE was 0.68. Addition of lipocalin-2 to the age-clinical risk factor model improved predictive accuracy (area under the curve=0.73). Area under the curve further increased to 0.75 when a combination of lipocalin-2, A-FABP, and FGF-19 was added to yield age-biomarkers-clinical risk factor model. The adjusted hazard ratio on MACEs for lipocalin-2, A-FABP, and FGF-19 levels above optimal cutoffs were 2.23 (95% CI, 1.62-3.08), 1.99 (95% CI, 1.43-2.76), and 1.65 (95% CI, 1.15-2.35), respectively. In the validation cohort of 1262 coronary artery disease patients with type 2 diabetes mellitus, the age-biomarkers-clinical risk factor model was confirmed to provide good discrimination and calibration over the conventional risk factor alone for prediction of MACE. Conclusions- A combination of the 3 biomarkers, lipocalin-2, A-FABP, and FGF-19, with clinical risk factors to yield the age-biomarkers-clinical risk factor model provides an optimal and validated prediction of new-onset MACE in patients with stable coronary artery disease.
Collapse
Affiliation(s)
- Yuen-Kwun Wong
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China
| | - Chloe Y Y Cheung
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China
| | - Clara S Tang
- Department of Surgery (C.S.T.), the University of Hong Kong, China
| | - Ka-Wing Au
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China
| | - JoJo S H Hai
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China
| | - Chi-Ho Lee
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China
| | - Kui-Kai Lau
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China
| | - Bernard M Y Cheung
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China
| | - Pak-Chung Sham
- Department of Psychiatry (P.-C.S.), the University of Hong Kong, China.,Centre for Genomic Sciences, Li Ka Shing Faculty of Medicine (P.-C.S.), the University of Hong Kong, China.,State Key Laboratory in Brain and Cognitive Sciences (P.-C.S.), the University of Hong Kong, China
| | - Aimin Xu
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China.,State Key Laboratory of Pharmaceutical Biotechnology (A.X., K.S.L.L.), the University of Hong Kong, China.,Department of Pharmacology & Pharmacy (A.X.), the University of Hong Kong, China
| | - Karen S L Lam
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China.,State Key Laboratory of Pharmaceutical Biotechnology (A.X., K.S.L.L.), the University of Hong Kong, China
| | - Hung-Fat Tse
- From the Department of Medicine (Y.-K.W., C.Y.Y.C., K.-W.A., J.S.H.H., C.-H.L., K.-K.L., B.M.Y.C., A.X., K.S.L.L., H.-F.T.), the University of Hong Kong, China.,Hong Kong-Guangdong Joint Laboratory on Stem Cell and Regenerative Medicine (H.-F.T.), the University of Hong Kong, China.,Shenzhen Institutes of Research and Innovation (H.-F.T.), the University of Hong Kong, China.,Department of Medicine, Shenzhen Hong Kong University Hospital, China (H.-F.T.)
| |
Collapse
|
8
|
Marino BCA, Buljubasic N, Akkerhuis M, Cheng JM, Garcia-Garcia HM, Regar E, Geuns RJV, Serruys PW, Boersma E, Kardys I. Adiponectin in Relation to Coronary Plaque Characteristics on Radiofrequency Intravascular Ultrasound and Cardiovascular Outcome. Arq Bras Cardiol 2019; 111:345-353. [PMID: 30379252 PMCID: PMC6173335 DOI: 10.5935/abc.20180172] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Accepted: 04/11/2018] [Indexed: 02/05/2023] Open
Abstract
Background Prospective data on the associations of adiponectin with in-vivo measurements
of degree, phenotype and vulnerability of coronary atherosclerosis are
currently lacking. Objective To investigate the association of plasma adiponectin with virtual histology
intravascular ultrasound (VH-IVUS)-derived measures of atherosclerosis and
with major adverse cardiac events (MACE) in patients with established
coronary artery disease. Methods In 2008-2011, VH-IVUS of a non-culprit non-stenotic coronary segment was
performed in 581 patients undergoing coronary angiography for acute coronary
syndrome (ACS, n = 318) or stable angina pectoris (SAP, n = 263) from the
atherosclerosis-intravascular ultrasound (ATHEROREMO-IVUS) study. Blood was
sampled prior to coronary angiography. Coronary plaque burden, tissue
composition, high-risk lesions, including VH-IVUS-derived thin-cap
fibroatheroma (TCFA), were assessed. All-cause mortality, ACS, unplanned
coronary revascularization were registered during a 1-year-follow-up. All
statistical tests were two-tailed and p-values < 0.05 were considered
statistically significant. Results In the full cohort, adiponectin levels were not associated with plaque
burden, nor with the various VH-tissue types. In SAP patients, adiponectin
levels (median[IQR]: 2.9(1.9-3.9) µg/mL) were
positively associated with VH-IVUS derived TCFA lesions, (OR[95%CI]:
1.78[1.06-3.00], p = 0.030), and inversely associated with lesions with
minimal luminal area (MLA) ≤ 4.0 mm2 (OR[95%CI]:
0.55[0.32-0.92], p = 0.025). In ACS patients, adiponectin levels
(median[IQR]: 2.9 [1.8-4.1] µg/mL)were not
associated with plaque burden, nor with tissue components. Positive
association of adiponectin with death was present in the full cohort
(HR[95%CI]: 2.52[1.02-6.23], p = 0.045) and (borderline) in SAP patients
(HR[95%CI]: 8.48[0.92-78.0], p = 0.058). In ACS patients, this association
lost statistical significance after multivariable adjustment (HR[95%CI]:
1.87[0.67-5.19], p = 0.23). Conclusion In the full cohort, adiponectin levels were associated with death but not
with VH-IVUS atherosclerosis measures. In SAP patients, adiponectin levels
were associated with VH-IVUS-derived TCFA lesions. Altogether, substantial
role for adiponectin in plaque vulnerability remains unconfirmed.
Collapse
Affiliation(s)
- Bárbara Campos Abreu Marino
- Department of Cardiology, Erasmus MC, Rotterdam - the Netherlands.,Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG - Brasil
| | | | | | - Jin M Cheng
- Department of Cardiology, Erasmus MC, Rotterdam - the Netherlands
| | | | - Evelyn Regar
- Department of Cardiology, Erasmus MC, Rotterdam - the Netherlands.,University Hospital of Zurich, Zurich - Switzerland
| | | | | | - Eric Boersma
- Department of Cardiology, Erasmus MC, Rotterdam - the Netherlands
| | - Isabella Kardys
- Department of Cardiology, Erasmus MC, Rotterdam - the Netherlands
| |
Collapse
|
9
|
Aubert CE, Liabeuf S, Amouyal C, Kemel S, Lajat-Kiss F, Lacorte JM, Halbron M, Carlier A, Salem JE, Funck-Brentano C, Perisic Matic L, Witasp A, Stenvinkel P, Phan F, Massy ZA, Hartemann A, Bourron O. Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy. Diabetol Metab Syndr 2019; 11:32. [PMID: 31168327 PMCID: PMC6489190 DOI: 10.1186/s13098-019-0429-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 04/17/2019] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Medial calcification in diabetes contributes to the arterial occlusive process occurring below the knee level. Adiponectin is an adipokine with atheroprotective properties and possible protective role against arterial calcification. The aim of the study was to investigate, in type 2 diabetes, the link between vascular expression and serum concentration of adiponectin and (1) peripheral arterial calcification and (2) lower limb occlusive arterial disease. METHODS Scoring of peripheral vascular calcification and peripheral arterial occlusive disease, using CT-scan and color-duplex ultrasonography respectively, were conducted and explored in relation to serum adiponectin level in a cross sectional study of 197 patients with type 2 diabetes. Vascular adiponectin expression in the arterial wall of diabetic patients with and without medial calcification was evaluated by immunohistochemistry. RESULTS Peripheral arterial calcification score was higher in patients with the highest adiponectin concentration. In a multivariate logistic regression analysis, an increase of 1 µg/mL of adiponectin was associated with a 22% increase of arterial calcification (adjusted OR = 1.22; 95% CI 1.03-1.44; p = 0.02). Arterial occlusive score was also higher in patients with adiponectin concentration > median (2.8 ± 4.8 vs 4.2 ± 5.7, p = 0.034). Immunohistochemical analyses showed a strong and specific staining of adiponectin in smooth muscle cells in calcified arteries, with a more pronounced expression of adiponectin in early stages of medial calcification. CONCLUSIONS Peripheral arterial calcification is positively associated with circulating adiponectin levels in patients with type 2 diabetes, but vascular adiponectin expression is already observed at early stages of calcification. Adiponectin secretion could be a compensatory mechanism against the calcification process.Trial registration DIACART NCT number: NCT02431234. Registered 30 April 2015.
Collapse
Affiliation(s)
- Carole E. Aubert
- Assistance Publique-Hôpitaux de Paris (APHP), Diabetology Department, Pitié Salpêtrière Hospital, 47-83 Boulevard de l’Hôpital, Paris, France
| | - Sophie Liabeuf
- INSERM U1088, UFR de Médecine et Pharmacie, Jules Verne University of Picardy, Amiens, France
- Clinical Research Centre, Division of Clinical Pharmacology, Amiens University Hospital and the Jules Verne University of Picardy, Amiens, France
| | - Chloé Amouyal
- Sorbonne Université, UPMC Univ, Paris 06, France
- Assistance Publique-Hôpitaux de Paris (APHP), Diabetology Department, Pitié Salpêtrière Hospital, 47-83 Boulevard de l’Hôpital, Paris, France
- Institute of Cardiometabolism and Nutrition ICAN, Paris, France
| | - Salim Kemel
- Cardiovascular and Interventional Radiology Department, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | | | - Jean-Marc Lacorte
- Sorbonne Université, UPMC Univ, Paris 06, France
- Department of Endocrine and Oncologic Biochemistry, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
- Institute of Cardiometabolism and Nutrition ICAN, Paris, France
- INSERM U1166, Paris, France
| | - Marine Halbron
- Assistance Publique-Hôpitaux de Paris (APHP), Diabetology Department, Pitié Salpêtrière Hospital, 47-83 Boulevard de l’Hôpital, Paris, France
- Institute of Cardiometabolism and Nutrition ICAN, Paris, France
| | - Aurélie Carlier
- Sorbonne Université, UPMC Univ, Paris 06, France
- Assistance Publique-Hôpitaux de Paris (APHP), Diabetology Department, Pitié Salpêtrière Hospital, 47-83 Boulevard de l’Hôpital, Paris, France
- Institute of Cardiometabolism and Nutrition ICAN, Paris, France
| | - Joe-Elie Salem
- Sorbonne Université, UPMC Univ, Paris 06, France
- Institute of Cardiometabolism and Nutrition ICAN, Paris, France
- Department of Pharmacology and CIC-1421, AP-HP, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
- INSERM, CIC-1421, Paris, France
| | - Christian Funck-Brentano
- Sorbonne Université, UPMC Univ, Paris 06, France
- Institute of Cardiometabolism and Nutrition ICAN, Paris, France
- Department of Pharmacology and CIC-1421, AP-HP, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
- INSERM, CIC-1421, Paris, France
| | - Ljubica Perisic Matic
- Division of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
- Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Anna Witasp
- Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Peter Stenvinkel
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Franck Phan
- Sorbonne Université, UPMC Univ, Paris 06, France
- Assistance Publique-Hôpitaux de Paris (APHP), Diabetology Department, Pitié Salpêtrière Hospital, 47-83 Boulevard de l’Hôpital, Paris, France
- Institute of Cardiometabolism and Nutrition ICAN, Paris, France
| | - Ziad A. Massy
- Division of Nephrology, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France
- INSERM U1018, Research Centre in Epidemiology and Population Health (CESP) Team 5, University of Paris Saclay-Versailles-St-Quentin-en-Yvelines (UVSQ), Villejuif, France
| | - Agnès Hartemann
- Sorbonne Université, UPMC Univ, Paris 06, France
- Assistance Publique-Hôpitaux de Paris (APHP), Diabetology Department, Pitié Salpêtrière Hospital, 47-83 Boulevard de l’Hôpital, Paris, France
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06, France
- Institute of Cardiometabolism and Nutrition ICAN, Paris, France
| | - Olivier Bourron
- Sorbonne Université, UPMC Univ, Paris 06, France
- Assistance Publique-Hôpitaux de Paris (APHP), Diabetology Department, Pitié Salpêtrière Hospital, 47-83 Boulevard de l’Hôpital, Paris, France
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06, France
- Institute of Cardiometabolism and Nutrition ICAN, Paris, France
| |
Collapse
|
10
|
Schrieks IC, Nozza A, Stähli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Rydén L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care 2018; 41:1792-1800. [PMID: 29903845 DOI: 10.2337/dc18-0158] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Accepted: 04/25/2018] [Indexed: 02/03/2023]
Abstract
OBJECTIVE In observational cohorts, adiponectin is inversely associated and free fatty acids (FFAs) are directly associated with incident coronary heart disease (CHD). Adiponectin tends to be reduced and FFAs elevated in type 2 diabetes. We investigated relationships of adiponectin and FFA and major adverse cardiovascular events (MACEs) and death in patients with acute coronary syndrome (ACS) and type 2 diabetes using data from the AleCardio (Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus) trial, which compared the PPAR-α/γ agonist aleglitazar with placebo. RESEARCH DESIGN AND METHODS Using Cox regression adjusted for demographic, laboratory, and treatment variables, we determined associations of baseline adiponectin and FFAs, or the change in adiponectin and FFAs from baseline, with MACEs (cardiovascular death, myocardial infarction, or stroke) and death. RESULTS A twofold higher baseline adiponectin (n = 6,998) was directly associated with risk of MACEs (hazard ratio [HR] 1.17 [95% CI 1.08-1.27]) and death (HR 1.53 [95% CI 1.35-1.73]). A doubling of adiponectin from baseline to month 3 (n = 6,325) was also associated with risk of death (HR 1.20 [95% CI 1.03-1.41]). Baseline FFAs (n = 7,038), but not change in FFAs from baseline (n = 6,365), were directly associated with greater risk of MACEs and death. There were no interactions with study treatment. CONCLUSIONS In contrast to prior observational data for incident CHD, adiponectin is prospectively associated with MACEs and death in patients with type 2 diabetes and ACS, and an increase in adiponectin from baseline is directly related to death. These findings raise the possibility that adiponectin has different effects in patients with type 2 diabetes and ACS than in populations without prevalent cardiovascular disease. Consistent with prior data, FFAs are directly associated with adverse outcomes.
Collapse
Affiliation(s)
- Ilse C Schrieks
- Julius Clinical and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Anna Nozza
- Montreal Health Innovations Coordinating Center, Montreal Heart Institute, Montreal, Canada
| | - Barbara E Stähli
- Department of Cardiology, Charité Berlin-University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - John B Buse
- University of North Carolina School of Medicine, Chapel Hill, NC
| | | | - Klas Malmberg
- Karolinska Institutet and Vicore Pharma, Stockholm, Sweden
| | - Bruce Neal
- The George Institute for Global Health, University of Sydney, Sydney, Australia
| | - Stephen J Nicholls
- South Australian Health and Medical Research Institute, The University of Adelaide, Adelaide, Australia
| | - Lars Rydén
- Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
| | - Linda Mellbin
- Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
| | | | - Hans Wedel
- Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | | | - A Michael Lincoff
- Department of Cardiovascular Medicine, Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH
| | | | - Diederick E Grobbee
- Julius Clinical and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Gregory G Schwartz
- Division of Cardiology, VA Medical Center and University of Colorado School of Medicine, Denver, CO
| |
Collapse
|
11
|
Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome. Biomolecules 2018; 8:biom8030060. [PMID: 30037035 PMCID: PMC6163749 DOI: 10.3390/biom8030060] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 07/09/2018] [Accepted: 07/16/2018] [Indexed: 02/08/2023] Open
Abstract
Acute myocardial infarction remains a leading cause of morbidity and mortality. While iron deficient heart failure patients are at increased risk of future cardiovascular events and see improvement with intravenous supplementation, the clinical relevance of iron deficiency in acute coronary syndrome remains unclear. We aimed to evaluate the prognostic value of iron deficiency in the acute coronary syndrome (ACS). Levels of ferritin, iron, and transferrin were measured at baseline in 836 patients with ACS. A total of 29.1% was categorized as iron deficient. The prevalence of iron deficiency was clearly higher in women (42.8%), and in patients with anemia (42.5%). During a median follow-up of 4.0 years, 111 subjects (13.3%) experienced non-fatal myocardial infarction (MI) and cardiovascular mortality as combined endpoint. Iron deficiency strongly predicted non-fatal MI and cardiovascular mortality with a hazard ratio (HR) of 1.52 (95% confidence interval (CI) 1.03-2.26; p = 0.037) adjusted for age, sex, hypertension, smoking status, diabetes, hyperlipidemia, body-mass-index (BMI) This association remained significant (HR 1.73 (95% CI 1.07⁻2.81; p = 0.026)) after an additional adjustment for surrogates of cardiac function and heart failure severity (N-terminal pro B-type natriuretic peptide, NT-proBNP), for the size of myocardial necrosis (troponin), and for anemia (hemoglobin). Survival analyses for cardiovascular mortality and MI provided further evidence for the prognostic relevance of iron deficiency (HR 1.50 (95% CI 1.02⁻2.20)). Our data showed that iron deficiency is strongly associated with adverse outcome in acute coronary syndrome.
Collapse
|
12
|
Tanaka A, Yoshida H, Kawaguchi A, Oyama JI, Kotooka N, Toyoda S, Inoue T, Natsuaki M, Node K. N-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study. Sci Rep 2017; 7:5810. [PMID: 28724951 PMCID: PMC5517578 DOI: 10.1038/s41598-017-06090-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 06/07/2017] [Indexed: 12/16/2022] Open
Abstract
Few data on clinical characteristics associated with N-terminal pro-brain natriuretic peptide (NT-proBNP) or the clinical value of measuring NT-proBNP in the working population are available. The aim of the present study was to investigate the levels of NT-proBNP and their association with clinical variables in the Japanese general working population by using baseline data from the Uranosaki cohort study. In the study, the plasma concentration of NT-proBNP and some biomarkers were measured in addition to the standard health checkups at the workplace. Questionnaires regarding health-related quality of life (HR-QOL) were also completed. A total of 2140 participants were enrolled in the study. Plasma levels of NT-proBNP were positively associated with age, female sex, systolic blood pressure, pulse pressure, prevalent hypertension, smoking habit, high-density lipoprotein cholesterol (HDL-C), and prevalent proteinuria, and negatively associated with body mass index, lipid profiles except HDL-C, uric acid, renal function, and hemoglobin. Both the plasma concentration of high-molecular weight adiponectin and that of high-sensitivity troponin T were positively and independently associated with NT-proBNP. In addition, the HR-QOL score regarding sleep disorder was independently associated with NT-proBNP. Thus, we have obtained evidence that the plasma NT-proBNP is affected by several clinical variables in the general working population.
Collapse
Affiliation(s)
- Atsushi Tanaka
- Department of Cardiovascular Medicine, Saga University, Saga, Japan.
| | | | | | - Jun-Ichi Oyama
- Department of Cardiovascular Medicine, Saga University, Saga, Japan
| | - Norihiko Kotooka
- Department of Cardiovascular Medicine, Saga University, Saga, Japan
| | - Shigeru Toyoda
- Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan
| | - Teruo Inoue
- Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan
| | - Masafumi Natsuaki
- Department of Internal Medicine, Imari Matsuura Hospital, Imari, Japan
| | - Koichi Node
- Department of Cardiovascular Medicine, Saga University, Saga, Japan.
| |
Collapse
|
13
|
Feistritzer HJ, Klug G, Reinstadler SJ, Reindl M, Mayr A, Mair J, Metzler B. Novel biomarkers predicting cardiac function after acute myocardial infarction. Br Med Bull 2016; 119:63-74. [PMID: 27418651 DOI: 10.1093/bmb/ldw027] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/12/2016] [Indexed: 12/24/2022]
Abstract
BACKGROUND Measurement of biomarkers provides a cost-effective and widely available method to estimate cardiac dysfunction and clinical outcome of patients with acute myocardial infarction (AMI). SOURCES OF DATA PubMed entries with terms 'myocardial infarction' and the respective biomarker. AREAS OF AGREEMENT Cardiac troponins and natriuretic peptides are closely related to left ventricular dysfunction and the occurrence of adverse clinical events following AMI. AREAS OF CONTENTION The incremental value of novel biomarkers is controversial. FUTURE DIRECTIONS The combination of traditional and novel biomarkers might further improve risk stratification of patients with AMI. SEARCH STRATEGY We searched all entries on the PubMed database with the MeSH terms 'myocardial infarction' and 'cardiac troponins', 'natriuretic peptides', 'copeptin', galectin-3', 'corin', 'fetuin-A', 'adiponectin' and 'microRNA'.
Collapse
Affiliation(s)
- Hans-Josef Feistritzer
- Department of Cardiology and Angiology, University Clinic of Internal Medicine III, Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
| | - Gert Klug
- Department of Cardiology and Angiology, University Clinic of Internal Medicine III, Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
| | - Sebastian J Reinstadler
- Department of Cardiology and Angiology, University Clinic of Internal Medicine III, Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
| | - Martin Reindl
- Department of Cardiology and Angiology, University Clinic of Internal Medicine III, Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
| | - Agnes Mayr
- Department of Radiology, Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
| | - Johannes Mair
- Department of Cardiology and Angiology, University Clinic of Internal Medicine III, Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
| | - Bernhard Metzler
- Department of Cardiology and Angiology, University Clinic of Internal Medicine III, Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
| |
Collapse
|
14
|
Pratesi A, Di Serio C, Orso F, Foschini A, Bartoli N, Marella A, Fumagalli S, Di Bari M, Marchionni N, Tarantini F, Baldasseroni S. Prognostic value of adiponectin in coronary artery disease: Role of diabetes and left ventricular systolic dysfunction. Diabetes Res Clin Pract 2016; 118:58-66. [PMID: 27344545 DOI: 10.1016/j.diabres.2016.04.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Revised: 03/16/2016] [Accepted: 04/14/2016] [Indexed: 11/24/2022]
Abstract
OBJECTIVES Adiponectin (AD) promotes insulin sensitivity and has anti-atherogenic properties. However, the role of AD on clinical outcomes in coronary artery disease (CAD) is controversial. We analyzed whether AD was an independent predictor of all-cause mortality and hospitalization in patients with CAD. METHOD We prospectively enrolled 138 patients with stable CAD, with or without type 2 diabetes and with or without left ventricular dysfunction. A telephone follow-up was conducted to register long term outcomes. Sensitivity/specificity ratio for AD was investigated with ROC analysis and the independent role of AD on outcome was evaluated with Cox regression model of analysis. The survival rate was represented by Kaplan Meyer curves. RESULTS Of 138 patients, 61 had type 2 diabetes and 71 left ventricular systolic dysfunction (EF<40%). Median time of follow-up was 1384days; mortality rate was 18.8% (26 deaths) and hospitalization rate was 47.1% (65 events). Mean concentration of AD was 9.87±7.53ng/ml; the analysis of the ROC curve identified an AD cut-off level of 13.2ng/ml (AUC 0.779; p<0.0001). Patients with AD >13.2ng/ml had a significantly higher risk of death (HR=6.50; 95% CI: 2.40-17.70), but not of cardiovascular hospitalization (HR=0.87; 95% CI: 0.31-2.44). AD predictivity remained significant also in patients with type 2 diabetes and with left ventricular systolic dysfunction. CONCLUSION In stable CAD, an AD value of >13.2ng/ml independently predicts a 6-fold increased risk of all-cause mortality.
Collapse
Affiliation(s)
- Alessandra Pratesi
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Claudia Di Serio
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Francesco Orso
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Alice Foschini
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Nadia Bartoli
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Andrea Marella
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Stefano Fumagalli
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Mauro Di Bari
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Niccolò Marchionni
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Francesca Tarantini
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
| | - Samuele Baldasseroni
- Division of Geriatric Cardiology and Medicine, Research Unit of Medicine of Ageing, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy; Intensive Care Unit, Division of Cardiology, Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi (AOUC), Florence, Italy.
| |
Collapse
|
15
|
Karakas M, Schulte C, Appelbaum S, Ojeda F, Lackner KJ, Münzel T, Schnabel RB, Blankenberg S, Zeller T. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study. Eur Heart J 2016; 38:516-523. [DOI: 10.1093/eurheartj/ehw250] [Citation(s) in RCA: 89] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Accepted: 05/31/2016] [Indexed: 12/28/2022] Open
|
16
|
Antonopoulos AS, Margaritis M, Verheule S, Recalde A, Sanna F, Herdman L, Psarros C, Nasrallah H, Coutinho P, Akoumianakis I, Brewer AC, Sayeed R, Krasopoulos G, Petrou M, Tarun A, Tousoulis D, Shah AM, Casadei B, Channon KM, Antoniades C. Mutual Regulation of Epicardial Adipose Tissue and Myocardial Redox State by PPAR-γ/Adiponectin Signalling. Circ Res 2016; 118:842-55. [PMID: 26838789 PMCID: PMC4772814 DOI: 10.1161/circresaha.115.307856] [Citation(s) in RCA: 107] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Accepted: 01/21/2016] [Indexed: 01/09/2023]
Abstract
RATIONALE Adiponectin has anti-inflammatory effects in experimental models, but its role in the regulation of myocardial redox state in humans is unknown. Although adiponectin is released from epicardial adipose tissue (EpAT), it is unclear whether it exerts any paracrine effects on the human myocardium. OBJECTIVE To explore the cross talk between EpAT-derived adiponectin and myocardial redox state in the human heart. METHODS AND RESULTS EpAT and atrial myocardium were obtained from 306 patients undergoing coronary artery bypass grafting. Functional genetic polymorphisms that increase ADIPOQ expression (encoding adiponectin) led to reduced myocardial nicotinamide adenine dinucleotide phosphate oxidase-derived O2 (-), whereas circulating adiponectin and ADIPOQ expression in EpAT were associated with elevated myocardial O2 (-). In human atrial tissue, we demonstrated that adiponectin suppresses myocardial nicotinamide adenine dinucleotide phosphate oxidase activity, by preventing AMP kinase-mediated translocation of Rac1 and p47(phox) from the cytosol to the membranes. Induction of O2 (-) production in H9C2 cardiac myocytes led to the release of a transferable factor able to induce peroxisome proliferator-activated receptor-γ-mediated upregulation of ADIPOQ expression in cocultured EpAT. Using a NOX2 transgenic mouse and a pig model of rapid atrial pacing, we found that oxidation products (such as 4-hydroxynonenal) released from the heart trigger peroxisome proliferator-activated receptor-γ-mediated upregulation of ADIPOQ in EpAT. CONCLUSIONS We demonstrate for the first time in humans that adiponectin directly decreases myocardial nicotinamide adenine dinucleotide phosphate oxidase activity via endocrine or paracrine effects. Adiponectin expression in EpAT is controlled by paracrine effects of oxidation products released from the heart. These effects constitute a novel defense mechanism of the heart against myocardial oxidative stress.
Collapse
Affiliation(s)
- Alexios S Antonopoulos
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Marios Margaritis
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Sander Verheule
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Alice Recalde
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Fabio Sanna
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Laura Herdman
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Costas Psarros
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Hussein Nasrallah
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Patricia Coutinho
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Ioannis Akoumianakis
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Alison C Brewer
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Rana Sayeed
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - George Krasopoulos
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Mario Petrou
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Akansha Tarun
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Dimitris Tousoulis
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Ajay M Shah
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Barbara Casadei
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Keith M Channon
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.)
| | - Charalambos Antoniades
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., A.R., F.S., L.H., C.P., P.C., I.A., A.T., B.C., K.M.C., C.A.); Cardiac Electrophysiology Group, Department of Physiology, Maastricht University, Maastricht, The Netherlands (S.V., H.N.); Department of Cardiology, Athens University Medical School, Athens, Greece (D.T.); Cardiovascular Division, King's College London BHF Centre, London, United Kingdom (A.C.B., A.M.S.); and Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.S., G.K., M.P.).
| |
Collapse
|
17
|
Sopić M, Joksić J, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Anđelković K, Jelić-Ivanović Z. Are decreased AdipoR1 mRNA levels associated with adiponectin resistance in coronary artery disease patients? Clin Exp Pharmacol Physiol 2015; 42:331-6. [PMID: 25582653 DOI: 10.1111/1440-1681.12361] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Revised: 12/23/2014] [Accepted: 01/04/2015] [Indexed: 12/15/2022]
Abstract
The aim of the present study was to investigate if circulating adiponectin levels and the expression of AdipoR1 and AdipoR2 in peripheral blood mononuclear cells (PBMC) are altered in coronary artery disease (CAD) patients, with and without significant stenosis, compared to healthy patients. The present study included 69 patients with presenting symptoms of CAD (26 patients with significant stenosis and 43 patients without significant stenosis). The control group (CG) consisted of 33 healthy patients. Circulating adiponectin levels were measured by enzyme-linked immunosorbent assay, whereas AdipoR1 and AdipoR2 mRNA levels in PBMC were determined by real-time polymerase chain reaction. Adiponectin levels were significantly higher in patients with and without significant stenosis compared to the CG (P < 0.001 vs P = 0.006, respectively). Both patient groups had lower AdipoR1 levels compared to the CG (P < 0.001 vs P < 0.001, respectively). There were no significant differences in these parameters between the two patient groups. Adiponectin negatively correlated with body mass index, triglycerides, insulin and homeostasis model assessment of insulin resistance index (HOMA IR), and positively with high-denisty lipoprotein cholesterol in the CG. Glucose, insulin, and the HOMA IR index negatively correlated with adiponectin in patients. A positive correlation between adiponectin receptors was found in patients and the CG. Decreased AdipoR1 mRNA levels and increased circulating adiponectin in advanced stages of CAD, as well as in patients without significant stenosis, compared to the CG, implies that CAD could be related to 'adiponectin resistance'. Despite increased adiponectin, its protective effects could be diminished even in early stages of atherosclerosis.
Collapse
Affiliation(s)
- Miron Sopić
- Department of Medical Biochemistry, University of Belgrade, Belgrade, Serbia
| | | | | | | | | | | |
Collapse
|
18
|
Lindberg S, Jensen JS, Hoffmann S, Pedersen SH, Iversen AZ, Galatius S, Frystyk J, Flyvbjerg A, Goetze JP, Bjerre M, Mogelvang R. Interplay Between Adiponectin and Pro-Atrial Natriuretic Peptide and Prognosis in Patients With ST-Segment Elevation Myocardial Infarction. Am J Cardiol 2015; 116:1340-5. [PMID: 26361828 DOI: 10.1016/j.amjcard.2015.07.060] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 07/29/2015] [Accepted: 07/29/2015] [Indexed: 12/13/2022]
Abstract
Natriuretic peptides (NPs) may regulate adipocyte metabolism including adiponectin. Infusion of atrial natriuretic peptide (ANP) increases plasma adiponectin in patients with heart failure. However, this relation has not been examined in a clinical setting or in myocardial infarction (MI). Accordingly, we investigated the interplay between proANP and adiponectin and the prognostic implications in patients with MI. We prospectively included 680 patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention from September 2006 to December 2008. Blood samples were drawn immediately before percutaneous coronary intervention. Additionally, we included 40 patients with 4 obtained blood samples during STEMI. Adiponectin and proANP were measured in all plasma samples. All patients were followed for 5 years. End points were all-cause mortality (n = 137) and the combined end point (n = 170) of major adverse cardiovascular events (MACEs). Plasma adiponectin and proANP were strongly associated at admission (r = 0.34, p <0.001). In patients with increasing proANP during STEMI, adiponectin also increased (0.5 ± 0.3 vs -0.1 ± 0.1 mg/L, p = 0.026). During follow-up, patients with higher adiponectin at admission had increased risk of all-cause mortality and MACE (both, p <0.001). After adjustment for confounding risk factors by Cox regression analysis, adiponectin remained an independent predictor of all-cause mortality and MACE: hazard ratio 1.31 (95% confidence interval 1.07 to 1.60; p = 0.009) and 1.31 (95% confidence interval 1.09 to 1.57; p = 0.004), respectively, for each SD increase. However, the association vanished when proANP was included in the analysis. In conclusion, adiponectin is associated with an increased risk of all-cause mortality and MACE. However, concomitantly elevated proANP levels appear to confound the association between adiponectin and worsened outcome.
Collapse
|
19
|
Alkofide H, Huggins GS, Ruthazer R, Beshansky JR, Selker HP. Serum adiponectin levels in patients with acute coronary syndromes: Serial changes and relation to infarct size. Diab Vasc Dis Res 2015; 12:411-9. [PMID: 26193887 PMCID: PMC5586528 DOI: 10.1177/1479164115592638] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND The role of adiponectin in patients with acute coronary syndromes is incompletely defined. This study investigated adiponectin levels in patients with acute coronary syndromes and the association between adiponectin and 30-day infarct size and 1-year clinical outcomes. METHODS Retrospective analysis of 120 participants with acute coronary syndromes enrolled in the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care Trial. Blood levels were tested three times within 24 h of onset of ischaemic symptoms. Infarct size was measured at 30 days. The 1-year clinical outcome was the composite of all-cause mortality or hospitalization for heart failure. RESULTS Using linear mixed models, log adiponectin levels decreased by -0.005 µg/mL per hour (p = 0.035). After stratifying the analysis by gender, there was no decrease in log adiponectin in men; however, levels decreased by -0.01 µg/mL per hour in women (p = 0.02). Results of multivariable regression models showed no association between log adiponectin and infarct size (β = -1.1, p = 0.64). Log adiponectin levels did not predict 1-year outcomes using Cox-proportional hazard models. CONCLUSION There was a small decrease in plasma adiponectin shortly after symptoms of ischaemia, more noticeable in women. No relationship was found between adiponectin and infarct size or clinical outcomes. This adds to evidence showing no clear association between adiponectin and adverse outcomes in patients with acute coronary syndromes.
Collapse
Affiliation(s)
- Hadeel Alkofide
- Clinical and Translational Science Graduate Program, Sackler School of Graduate Biomedical Sciences, Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA
| | - Gordon S Huggins
- MCRI Center for Translational Genomics, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, USA
| | - Robin Ruthazer
- Center for Cardiovascular Health Services Research, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA
| | - Joni R Beshansky
- Center for Cardiovascular Health Services Research, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA Regulatory and Clinical Research Management Graduate Program, Regis College, Weston, MA, USA
| | - Harry P Selker
- Center for Cardiovascular Health Services Research, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA
| |
Collapse
|
20
|
Ilisson J, Zagura M, Zilmer K, Salum E, Heilman K, Piir A, Tillmann V, Kals J, Zilmer M, Pruunsild C. Increased carotid artery intima-media thickness and myeloperoxidase level in children with newly diagnosed juvenile idiopathic arthritis. Arthritis Res Ther 2015; 17:180. [PMID: 26179062 PMCID: PMC4504074 DOI: 10.1186/s13075-015-0699-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Accepted: 06/26/2015] [Indexed: 12/19/2022] Open
Abstract
Introduction Juvenile idiopathic arthritis (JIA) is a frequent childhood rheumatic disease characterized by chronic inflammation. The latter has been related to impairment of arterial functional-structural properties, atherogenesis and later cardiovascular events. The objective of this study was to examine intima-media thickness (IMT) and the parameters of arterial stiffness in children with JIA at diagnosis and their correlation with JIA subtype and markers of inflammation and atherosclerosis. Methods Thirty-nine newly diagnosed patients with JIA (26 girls; mean age, 13.2 ± 2.6 years) and 27 healthy controls (9 girls; mean age, 13.6 ± 3.4 years) were included in the study. Twelve patients had oligoarthritis, fifteen had extended oligoarthritis and twelve had rheumatoid factor–negative polyarthritis. IMT of the common carotid artery was determined by ultrasonography, carotid-femoral pulse wave velocity (cfPWV) and augmentation index adjusted to a heart rate of 75 beats/min (AIx@75) were determined by applanation tonometry. The serum levels of atherosclerosis-related biomarkers, such as asymmetric dimethylarginine (ADMA), myeloperoxidase (MPO) and adiponectin, were measured by enzyme-linked immunosorbent assay. Results Mean IMT (0.46 ± 0.04 vs. 0.42 ± 0.04 mm; p = 0.0003) and MPO concentration (115.2 [95 % confidence interval {95 % CI}, 97.4–136.3] vs. 57.6 [95 % CI, 47.1–70.3] ng/ml; p < 0.0001) were higher in the patients with JIA than in the control subjects. The cfPWV, AIx@75 and serum ADMA and adiponectin levels did not significantly differ between the groups and JIA subtypes. Serum adiponectin level correlated negatively with AIx@75 in patients with JIA (r = −0.38; p < 0.05). Conclusions Patients with JIA have increased mean IMT and elevated MPO levels at early stages of the disease. AIx@75 was inversely independently associated with adiponectin level in the patients, suggesting that lower adiponectin levels might influence arterial subclinical stiffening in patients with newly diagnosed JIA.
Collapse
Affiliation(s)
- Jaanika Ilisson
- Department of Paediatrics, Faculty of Medicine, University of Tartu, Lunini 6, Tartu, 51014, Estonia. .,Children's Clinic, Tartu University Hospital, Tartu, Estonia.
| | - Maksim Zagura
- Department of Biochemistry, Institute of Biomedicine and Translational Medicine, The Centre of Excellence for Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia. .,Department of Cardiology, Faculty of Medicine, University of Tartu, Tartu, Estonia.
| | - Kersti Zilmer
- Department of Biochemistry, Institute of Biomedicine and Translational Medicine, The Centre of Excellence for Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
| | - Erik Salum
- Department of Cardiology, Faculty of Medicine, University of Tartu, Tartu, Estonia.
| | - Kaire Heilman
- Department of Paediatrics, Faculty of Medicine, University of Tartu, Lunini 6, Tartu, 51014, Estonia. .,Tallinn Children's Hospital, Tallinn, Estonia.
| | - Anneli Piir
- Department of Biochemistry, Institute of Biomedicine and Translational Medicine, The Centre of Excellence for Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
| | - Vallo Tillmann
- Department of Paediatrics, Faculty of Medicine, University of Tartu, Lunini 6, Tartu, 51014, Estonia. .,Children's Clinic, Tartu University Hospital, Tartu, Estonia.
| | - Jaak Kals
- Department of Biochemistry, Institute of Biomedicine and Translational Medicine, The Centre of Excellence for Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia. .,Department of Vascular Surgery, Tartu University Hospital, Tartu, Estonia.
| | - Mihkel Zilmer
- Department of Biochemistry, Institute of Biomedicine and Translational Medicine, The Centre of Excellence for Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
| | - Chris Pruunsild
- Department of Paediatrics, Faculty of Medicine, University of Tartu, Lunini 6, Tartu, 51014, Estonia. .,Children's Clinic, Tartu University Hospital, Tartu, Estonia.
| |
Collapse
|
21
|
Antonopoulos AS, Margaritis M, Coutinho P, Shirodaria C, Psarros C, Herdman L, Sanna F, De Silva R, Petrou M, Sayeed R, Krasopoulos G, Lee R, Digby J, Reilly S, Bakogiannis C, Tousoulis D, Kessler B, Casadei B, Channon KM, Antoniades C. Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human arterial wall: the regulatory role of perivascular adipose tissue. Diabetes 2015; 64:2207-19. [PMID: 25552596 DOI: 10.2337/db14-1011] [Citation(s) in RCA: 169] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Accepted: 12/20/2014] [Indexed: 12/25/2022]
Abstract
Oxidative stress plays a critical role in the vascular complications of type 2 diabetes. We examined the effect of type 2 diabetes on NADPH oxidase in human vessels and explored the mechanisms of this interaction. Segments of internal mammary arteries (IMAs) with their perivascular adipose tissue (PVAT) and thoracic adipose tissue were obtained from 386 patients undergoing coronary bypass surgery (127 with type 2 diabetes). Type 2 diabetes was strongly correlated with hypoadiponectinemia and increased vascular NADPH oxidase-derived superoxide anions (O2˙(-)). The genetic variability of the ADIPOQ gene and circulating adiponectin (but not interleukin-6) were independent predictors of NADPH oxidase-derived O2˙(-). However, adiponectin expression in PVAT was positively correlated with vascular NADPH oxidase-derived O2˙(-). Recombinant adiponectin directly inhibited NADPH oxidase in human arteries ex vivo by preventing the activation/membrane translocation of Rac1 and downregulating p22(phox) through a phosphoinositide 3-kinase/Akt-mediated mechanism. In ex vivo coincubation models of IMA/PVAT, the activation of arterial NADPH oxidase triggered a peroxisome proliferator-activated receptor-γ-mediated upregulation of the adiponectin gene in the neighboring PVAT via the release of vascular oxidation products. We demonstrate for the first time in humans that reduced adiponectin levels in individuals with type 2 diabetes stimulates vascular NADPH oxidase, while PVAT "senses" the increased NADPH oxidase activity in the underlying vessel and responds by upregulating adiponectin gene expression. This PVAT-vessel interaction is identified as a novel therapeutic target for the prevention of vascular complications of type 2 diabetes.
Collapse
Affiliation(s)
| | | | | | | | - Costas Psarros
- 1st Department of Cardiology, Athens University Medical School, Athens, Greece
| | - Laura Herdman
- Cardiovascular Medicine Division, University of Oxford, Oxford, U.K
| | - Fabio Sanna
- Cardiovascular Medicine Division, University of Oxford, Oxford, U.K
| | - Ravi De Silva
- Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, U.K
| | - Mario Petrou
- Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, U.K
| | - Rana Sayeed
- Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, U.K
| | | | - Regent Lee
- Cardiovascular Medicine Division, University of Oxford, Oxford, U.K
| | - Janet Digby
- Cardiovascular Medicine Division, University of Oxford, Oxford, U.K
| | - Svetlana Reilly
- Cardiovascular Medicine Division, University of Oxford, Oxford, U.K
| | | | - Dimitris Tousoulis
- 1st Department of Cardiology, Athens University Medical School, Athens, Greece
| | - Benedikt Kessler
- Nuffield Department of Medicine, University of Oxford, Oxford, U.K
| | - Barbara Casadei
- Cardiovascular Medicine Division, University of Oxford, Oxford, U.K
| | - Keith M Channon
- Cardiovascular Medicine Division, University of Oxford, Oxford, U.K
| | | |
Collapse
|
22
|
Gavrilova NE, Metelskaya VA, Boytsov SA, Gumanova NG, Yarovaya EB. [Markers of visceral adipose tissue metabolic abnormalities in patients with coronary atherosclerosis in relation to the presence of type 2 diabetes mellitus]. TERAPEVT ARKH 2015; 87:31-36. [PMID: 26978171 DOI: 10.17116/terarkh2015871031-36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
AIM To assess the specific features of visceral adipose tissue metabolism in patients with coronary atherosclerosis, complicated or uncomplicated type 2 diabetes mellitus (T2DM). MATERIAL AND METHODS A cohort of 429 patients (325 men and 104 women; mean age, 61.3±9.4 years) with coronary atherosclerosis who had been admitted to the National Research Centre for Preventive Medicine, Ministry of Health of Russia, to undergo coronarography (CG) and to receive high-tech treatments and met the criteria for being included in and excluded from this investigation, was examined. The Gensini scoring scale was used to estimate the magnitude of coronary atherosclerosis from CG RESULTS: Carotid artery duplex ultrasound scanning estimating the intima-media thickness was performed in 48% of the patients. DM was diagnosed from examination results (fasting plasma glucose ≥7.0 mmol/l and glycated hemoglobin >6.5%) and an endocrinologist's report. 94% of the patients took statins. RESULTS Overall, 18% of the examinees had DM that was 2.5 times more common in the women than in the men (32.7 and 13.2%, respectively (p=0.000). The diabetic and non-diabetic patients showed no significant differences in age: 62.9±8.3 and 60.9±9.6 years, respectively (p=0.105). There were statistically significant differences in the magnitude of coronary artery atherosclerosis according to the Gensini scale in relation to the presence of T2DM; thus, the median Gensini score was 48 in the diabetic patients and 46 in the persons with no signs of the disease (Mann-Whitney test; p=0.03). Analysis of adipokine levels showed that the median leptin level was significantly higher than that in the male patients with T2DM than in the persons with no signs of the disease. In the patients with T2DM, the median adiponectin level turned out to be significantly lower in both men and women. CONCLUSION The coronary atherosclerosis severity rated using the Gensini scale is shown to increase in the presence of T2DM. The probability of detecting obvious (>45%) carotid artery lesion is associated with the presence of DM in both men and women. The male patients with T2DM concurrent with coronary atherosclerosis are noted to have an elevated leptin level, but a lower adiponectin concentration was found in both the men and women.
Collapse
Affiliation(s)
- N E Gavrilova
- National Research Center for Preventive Medicine, Moscow, Russia
| | - V A Metelskaya
- National Research Center for Preventive Medicine, Moscow, Russia
| | - S A Boytsov
- National Research Center for Preventive Medicine, Moscow, Russia
| | - N G Gumanova
- National Research Center for Preventive Medicine, Moscow, Russia
| | - E B Yarovaya
- National Research Center for Preventive Medicine, Moscow, Russia
| |
Collapse
|
23
|
Fisher L, Srikusalanukul W, Fisher A, Smith P. Liver function parameters in hip fracture patients: relations to age, adipokines, comorbidities and outcomes. Int J Med Sci 2015; 12:100-15. [PMID: 25589886 PMCID: PMC4293175 DOI: 10.7150/ijms.10696] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Accepted: 04/11/2014] [Indexed: 02/07/2023] Open
Abstract
AIM To asses liver markers in older patients with hip fracture (HF) in relation to age, comorbidities, metabolic characteristics and short-term outcomes. METHODS In 294 patients with HF (mean age 82.0±7.9 years, 72.1% women) serum alanine aminotransferase (ALT), gammaglutamyltransferase (GGT), alkaline phosphatase (ALP), albumin, bilirubin, 25(OH)vitaminD, PTH, calcium, phosphate, magnesium, adiponectin, leptin, resistin, thyroid function and cardiac troponin I were measured. RESULTS Elevated ALT, GGT, ALP or bilirubin levels on admission were observed in 1.7%-9.9% of patients. With age GGT, ALT and leptin decrease, while PTH and adiponectin concentrations increase. Higher GGT (>30 U/L, median level) was associated with coronary artery disease (CAD), diabetes mellitus (DM), and alcohol overuse; lower ALT (≤20 U/L, median level) with dementia; total bilirubin>20 μmol/L with CAD and alcohol overuse; and albumin>33 g/L with CAD. Multivariate adjusted regression analyses revealed ALT, ALP, adiponectin, alcohol overuse and DM as independent and significant determinants of GGT (as continuous or categorical variable); GGT for each other liver marker; and PTH for adiponectin. The risk of prolonged hospital stay (>20 days) was about two times higher in patients with GGT>30 U/L or adiponectin>17.14 ng/L (median level) and 4.7 times higher if both conditions coexisted. The risk of in-hospital death was 3 times higher if albumin was <33 g/L. CONCLUSIONS In older HF patients liver markers even within the normal range are associated with age-related disorders and outcomes. Adiponectin (but not 25(OH)vitaminD, PTH, leptin or resistin) is an independent contributor to higher GGT. Serum GGT and albumin predict prolonged hospital stay and in-hospital death, respectively. A unifying hypothesis of the findings presented.
Collapse
Affiliation(s)
- Leon Fisher
- 1. Department of Gastroenterology, The Canberra Hospital, Canberra, ACT, Australia
| | - Wichat Srikusalanukul
- 2. Department of Geriatric Medicine, The Canberra Hospital, Canberra, ACT, Australia
| | - Alexander Fisher
- 2. Department of Geriatric Medicine, The Canberra Hospital, Canberra, ACT, Australia ; 4. Australian National University Medical School, Canberra, ACT, Australia
| | - Paul Smith
- 3. Department of Orthopaedic Surgery, The Canberra Hospital, Canberra, ACT, Australia ; 4. Australian National University Medical School, Canberra, ACT, Australia
| |
Collapse
|
24
|
Ivković V, Jelaković M, Laganović M, Pećin I, Vrdoljak A, Karanović S, Fuček M, Božina T, Kos J, Željković Vrkić T, Premužić V, Živko M, Jelaković B. Adiponectin is not associated with blood pressure in normotensives and untreated hypertensives with normal kidney function. Medicine (Baltimore) 2014; 93:e250. [PMID: 25526448 PMCID: PMC4603123 DOI: 10.1097/md.0000000000000250] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
The role of adiponectin in hypertension is still a matter of debate. Obtained conflicting results could be mostly explained with diversity of subjects included in different studies. Our aim was to analyze association of adiponectin with blood pressure (BP) in a group of normotensive and untreated hypertensive subjects. Participants (N=257) were selected from a random sample of 2487 subjects enrolled in an observational cross-sectional study. Subjects with diabetes and chronic kidney diseases were excluded. BP was measured using Omron M6 device following ESH/ESC guidelines. Adiponectin concentration was determined by ELISA. There were no differences in adiponectin values (mg/L) between hypertensives and normotensives (median 9.75; iqr: 7.44-17.88 vs 11.35; iqr: 7.43-12.63; P=0.17). On univariate linear regression adiponectin was not associated with systolic or diastolic BP (P>0.05). Furthermore, multivariate analysis did not show significant contribution of log-transformed adiponectin either to systolic (β=-0.040; P=0.43) or diastolic BP (β=0.066; P=0.33). In our group of normotensives and untreated hypertensives with normal kidney function adiponectin was not associated with BP even after adjustment for other risk factors. Our results and conclusions should not be extrapolated to subjects with other characteristics.
Collapse
Affiliation(s)
- Vanja Ivković
- From the School of Medicine, University of Zagreb, Croatia (VI, MJ); School of Medicine, University of Zagreb, Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, Croatia (ML, AV, SK, JK, TZ, VP, MZ, BJ); School of Medicine, University of Zagreb, Department of Metabolic Disorders, University Hospital Center Zagreb, Zagreb, Croatia (IP); and School of Medicine University of Zagreb, Clinical Department for Laboratory Diagnosis, University Hospital Center Zagreb, Zagreb, Croatia (MF, TB)
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Wu ZJ, Cheng YJ, Gu WJ, Aung LHH. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism 2014; 63:1157-66. [PMID: 24933398 DOI: 10.1016/j.metabol.2014.05.001] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2014] [Accepted: 05/05/2014] [Indexed: 01/19/2023]
Abstract
BACKGROUND The overall quantitative estimate on the possible association of adiponectin concentrations with mortality in patients with cardiovascular diseases (CVD) has not been reported. METHODS We performed a systematic review and meta-analysis of prospective studies to evaluate the overall quantitative estimates on the adiponectin levels for risk of mortality in patients with CVD. MEDLINE, EMBASE, CINAHL, and the Cochrane Library (up to Mar 22, 2014) were used to search for studies evaluating the effect of adiponectin levels on mortality in patients with CVD. Random-effect models were selected to estimate overall effect estimates. RESULTS Data from 14063 CVD patients enrolled in 15 prospective cohort and 1 nested case control studies were collated. The meta-analyses showed strong positive association of adiponectin with all-cause (n=14 studies, overall pooled effect estimate=1.45 [95% CI, 1.17-1.79]) and cardiovascular (n=11 studies, overall pooled effect estimate=1.69 [1.35-2.10]) mortality, for the highest tertile of adiponectin levels versus the lowest tertile. Subgroup analyses show study characteristics (including effect estimate, mean age, study location, sample sizes, gender, durations of follow-up, types of primary event, and acute or chronic CVD) did not substantially influence these positive associations. CONCLUSIONS Our results showed that increased baseline plasma adiponectin levels are significantly associated with elevated risk of all-cause and cardiovascular mortality in subjects with CVD. These positive associations may have been amplified by adjustment for potential intermediates or residual confounding, and their basis requires further investigation.
Collapse
Affiliation(s)
- Zhen-Jie Wu
- Department of Bone and Soft Tissue Neurosurgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
| | - Yun-Jiu Cheng
- Department of Cardiology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
| | - Wan-Jie Gu
- Department of Anaesthesiology, the First Affiliated Hospital, Guangxi Medical University, Nanning, China
| | - Lynn Htet Htet Aung
- Department of Cardiology, Institute of Cardiovascular Diseases, the First Affiliated Hospital, Guangxi Medical University, Nanning, China
| |
Collapse
|
26
|
Lisowska A, Lisowski P, Knapp M, Tycinska A, Sawicki R, Malyszko J, Hirnle T, Musial WJ. Serum adiponectin and markers of endothelial dysfunction in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG). Adv Med Sci 2014; 59:245-9. [PMID: 25108276 DOI: 10.1016/j.advms.2014.05.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2013] [Accepted: 04/28/2014] [Indexed: 12/29/2022]
Abstract
PURPOSE It has been established that endothelial dysfunction (ED) occurs after coronary artery bypass grafting (CABG). The aim of the study was to assess whether adiponectin may act as a novel marker of ED and its potential relations with new markers of ED: novel cell adhesion molecule CD146, a natural anti-thrombin glycoprotein - thrombomodulin (TM) and the well-established ED marker - Von Willebrand factor (VWF) in coronary artery disease (CAD) patients undergoing CABG. MATERIAL/METHODS 45 CAD patients undergoing elective CABG were included in the study. RESULTS In the study group the concentration of adiponectin and CD146 before the surgery were significantly lower than in the control group - 6.06 μg/ml ± 3.06 vs. 19.0 μg/ml ± 6.4 and 303.2 ng/ml ± 28.7 vs. 328.1 ng/ml ± 22.6 (p<0.05). Significant increase of adiponectin and CD146 concentration 3 months after CABG vs. before the surgery was found. Adiponectin concentration 3 months after CABG correlated with VWF, TM, CD146, and a number of grafts. CD146 before and 3 months after CABG correlated significantly with adiponectin, VWF activity as well as the statins therapy after the surgery. CONCLUSIONS In CAD patients undergoing CABG new markers of endothelial cell dysfunction as adiponectin and CD146 are significantly lower compared to healthy volunteers. Significant increase in adiponectin and CD146 concentration 3 months after CABG vs. before the surgery was found. However adiponectin concentrations 3 months after CABG were still significantly lower compared to healthy individuals, whereas CD146 concentration returned to the values comparable to the control.
Collapse
|
27
|
Antonopoulos AS, Margaritis M, Coutinho P, Digby J, Patel R, Psarros C, Ntusi N, Karamitsos TD, Lee R, De Silva R, Petrou M, Sayeed R, Demosthenous M, Bakogiannis C, Wordsworth PB, Tousoulis D, Neubauer S, Channon KM, Antoniades C. Reciprocal Effects of Systemic Inflammation and Brain Natriuretic Peptide on Adiponectin Biosynthesis in Adipose Tissue of Patients With Ischemic Heart Disease. Arterioscler Thromb Vasc Biol 2014; 34:2151-9. [DOI: 10.1161/atvbaha.114.303828] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
To explore the role of systemic inflammation in the regulation of adiponectin levels in patients with ischemic heart disease.
Approach and Results—
In a cross-sectional study of 575 subjects, serum adiponectin was compared between healthy subjects, patients with coronary artery disease with no/mild/severe heart failure (HF), and patients with nonischemic HF. Adiponectin expression and release from femoral, subcutaneous and thoracic adipose tissue was determined in 258 additional patients with coronary artery bypass grafting. Responsiveness of the various human adipose tissue depots to interleukin-6, tumor necrosis factor-α, and brain natriuretic peptide (BNP) was examined by using ex vivo models of human fat. The effects of inducible low-grade inflammation were tested by using the model of
Salmonella typhi
vaccine-induced inflammation in healthy individuals. In the cross-sectional study, HF strikingly increased adiponectin levels. Plasma BNP was the strongest predictor of circulating adiponectin and its release from all adipose tissue depots in patients with coronary artery bypass grafting, even in the absence of HF. Femoral AT was the depot with the least macrophages infiltration and the largest adipocyte cell size and the only responsive to systemic and ex vivo proinflammatory stimulation (effect reversible by BNP). Low-grade inflammation reduced circulating adiponectin levels, while circulating BNP remained unchanged.
Conclusions—
This study demonstrates the regional variability in the responsiveness of human adipose tissue to systemic inflammation and suggests that BNP (not systemic inflammation) is the main driver of circulating adiponectin in patients with advanced atherosclerosis even in the absence of HF. Any interpretation of circulating adiponectin as a biomarker should take into account the underlying disease state, background inflammation, and BNP levels.
Collapse
Affiliation(s)
- Alexios S. Antonopoulos
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Marios Margaritis
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Patricia Coutinho
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Janet Digby
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Rikhil Patel
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Constantinos Psarros
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Ntobeko Ntusi
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Theodoros D. Karamitsos
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Regent Lee
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Ravi De Silva
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Mario Petrou
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Rana Sayeed
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Michael Demosthenous
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Constantinos Bakogiannis
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Paul B. Wordsworth
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Dimitris Tousoulis
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Stefan Neubauer
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Keith M. Channon
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| | - Charalambos Antoniades
- From the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (A.S.A., M.M., P.C., J.D., R.P., N.N., T.D.K., R.L., S.N., K.M.C., C.A.); 1st Cardiology Department, Athens University Medical School, Athens, Greece (C.P., M.D., C.B., D.T.); Department of Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom (R.D.S., M.P., R.S.); and NIHR Oxford Musculoskeletal Biomedical Research Unit & Nuffield Department of Orthopaedics,
| |
Collapse
|
28
|
Herder C, Peltonen M, Svensson PA, Carstensen M, Jacobson P, Roden M, Sjöström L, Carlsson L. Adiponectin and bariatric surgery: associations with diabetes and cardiovascular disease in the Swedish Obese Subjects Study. Diabetes Care 2014; 37:1401-9. [PMID: 24574342 DOI: 10.2337/dc13-1362] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Adiponectin has been implicated in the pathogenesis of type 2 diabetes, but its role for incident diabetes, myocardial infarction, or stroke in obesity is unclear. The aim of this study was to analyze the associations between systemic levels of adiponectin and the aforementioned outcomes in a population with severe obesity at high risk of diabetes and cardiovascular events. RESEARCH DESIGN AND METHODS We measured serum concentrations of total adiponectin in 3,299 participants of the prospective controlled Swedish Obese Subjects (SOS) Study (bariatric surgery group, n = 1,570; control group given usual care, n = 1,729). Median follow-up periods ranged between 10 and 13 years for different outcomes. RESULTS In models containing both baseline adiponectin and 2-year changes in adiponectin, high baseline adiponectin and 2-year increases in adiponectin were associated with decreased risk of diabetes and myocardial infarction among controls. In the surgery group, the 2-year weight loss was paralleled by substantial increase in circulating adiponectin (1,807-1,958 ng/mL per 10-kg weight loss). However, neither baseline adiponectin nor 2-year increases in adiponectin were associated with risk of diabetes or myocardial infarction in the fully adjusted models in the surgery group. No associations were found for stroke in either group. CONCLUSIONS Taken together, baseline adiponectin and 2-year changes were associated with incident diabetes and myocardial infarction in the control group but not in the surgery group. Baseline adiponectin did not predict treatment benefit of bariatric surgery.
Collapse
|
29
|
Kishida K, Nakagawa Y, Kobayashi H, Mazaki T, Yokoi H, Yanagi K, Funahashi T, Shimomura I. High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome. Cardiovasc Diabetol 2014; 13:9. [PMID: 24400991 PMCID: PMC3893390 DOI: 10.1186/1475-2840-13-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2013] [Accepted: 01/02/2014] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND The complement system is part of the immune system in acute coronary syndrome (ACS). Adiponectin has anti-atherogenic and anti-inflammatory properties. Adiponectin and C1q form a protein complex in blood, and serum C1q binding adiponectin (C1q-APN) can be measured. We investigated the comparative evaluation of serum C1q-APN levels in males with ACS, stable angina pectoris (SAP) versus controls. METHODS The study subjects were 138 Japanese patients who underwent diagnostic coronary angiography. Blood total adiponectin (Total-APN), C1q-APN and C1q were measured by enzyme-linked immunosorbent assays. Patients were divided into three groups according to the clinical condition: ACS (n = 78), SAP (n = 41) or normal coronary (NC, n = 19) groups. RESULTS Serum C1q levels were significantly higher in the ACS group (54.9±1.2 μg/mL) than in the NC group (48.0±2.5 μg/mL). Although serum Total-APN levels were significantly lower in the SAP and ACS groups, compared with the NC group (7.0±0.5, 7.2±0.3, 10.6±2.0 μg/mL, respectively), serum C1q-APN levels were significantly higher in the ACS group than in the NC and SAP groups (112.1±4.1, 66.3±4.4, 65.7±2.9 units/mL, respectively). CONCLUSIONS Patients with ACS had higher serum C1q-APN levels. TRIAL REGISTRATION UMIN000002997.
Collapse
Affiliation(s)
- Ken Kishida
- Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Shen LJ, Yang SB, Lv QW, Zhang GH, Zhou J, Guo M, Huang HB, Li Z, Yang CS. High plasma adiponectin levels in patients with severe traumatic brain injury. Clin Chim Acta 2014; 427:37-41. [DOI: 10.1016/j.cca.2013.09.047] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2013] [Revised: 09/27/2013] [Accepted: 09/27/2013] [Indexed: 02/06/2023]
|
31
|
Kawagoe J, Ishikawa T, Iwakiri H, Date H, Imamura T, Kitamura K. Association Between Adiponectin Production in Coronary Circulation and Future Cardiovascular Events in Patients With Coronary Artery Disease. Int Heart J 2014; 55:239-43. [DOI: 10.1536/ihj.13-287] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- Junji Kawagoe
- Department of Internal Medicine, Division of Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki
| | - Tetsunori Ishikawa
- Department of Internal Medicine, Division of Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki
| | - Hironao Iwakiri
- Department of Cardiovascular Medicine, Miyakonojo Regional Medical Center
| | - Haruhiko Date
- Department of Cardiovascular Medicine, Jounan Hospital
| | - Takuroh Imamura
- Department of Cardiovascular Medicine, Koga General Hospital
| | - Kazuo Kitamura
- Department of Internal Medicine, Division of Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki
| |
Collapse
|
32
|
Sharma L, Dubey A, Gupta PR, Agrawal A. Androgenetic alopecia and risk of coronary artery disease. Indian Dermatol Online J 2013; 4:283-7. [PMID: 24350006 PMCID: PMC3853891 DOI: 10.4103/2229-5178.120638] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Background: Androgenetic alopecia (AGA) or male pattern baldness (MPB) has been found to be associated with the risk of coronary artery disease (CAD). The well-known risk factors are family history of CAD, hypertension, increased body mass index (BMI), central obesity, hyperglycemia, and dyslipidemia. The newer risk factors are serum lipoprotein-a (SL-a), serum homocysteine (SH), and serum adiponectin (SA). Aim: Identifying individuals at risk of CAD at an early age might help in preventing CAD and save life. Hence, a comparative study of CAD risk factors was planned in 100 males of AGA between the age of 25 and 40 years with equal number of age- and sex-matched controls. Materials and Methods: Patients of AGA grade II or more of Hamilton and Norwood (HN) Scale and controls were examined clinically and advised blood test. The reports were available for fasting blood sugar (FBS), serum total serum cholesterol (SC) in 64 cases, 64 controls; lipoproteins (high, low, very low density, HDL, LDL, VLDL), serum triglycerides (ST) in 63 cases, 63 controls; SL-a in 63 cases, 74 controls; SH in 56 cases, 74 controls; and SA in 62 cases, 74 controls. Results: In these cases family history (FH) of AGA and CAD was significantly high. The blood pressure (BP) was also found to be significantly high in the cases. The difference of mean serum HDL, LDL, VLDL, ST, SH, and SL-a in cases and controls were statistically significant and with increasing grade of AGA, the risk factors also increased. Conclusion: Patients with AGA appear to be at an increased risk of developing CAD, therefore, clinical evaluation of cases with AGA of grade II and above may be of help in preventing CAD in future.
Collapse
Affiliation(s)
- Lata Sharma
- Department of Dermatology and Venereology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
| | - Ajay Dubey
- Department of Dermatology and Venereology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
| | - P R Gupta
- Department of Cardiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
| | - Aruna Agrawal
- Department of Siddhant Darshan, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
| |
Collapse
|
33
|
Reinstadler SJ, Klug G, Feistritzer HJ, Mayr A, Bader K, Mair J, Esterhammer R, Schocke M, Metzler B. Relation of plasma adiponectin levels and aortic stiffness after acute ST-segment elevation myocardial infarction. EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE 2013; 3:10-7. [PMID: 24337918 DOI: 10.1177/2048872613516015] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
BACKGROUND Pulse wave velocity is a measure of aortic stiffness and an independent predictor of cardiovascular morbidity and mortality. Adiponectin is involved in atherosclerosis and inflammation. In the present study we aimed to explore the association between plasma adiponectin concentrations and pulse wave velocity in the acute phase after ST-segment elevation myocardial infarction (STEMI). METHODS Forty-six consecutive STEMI patients (mean age 57 ± 11 years) treated with primary percutaneous coronary intervention (PCI) were enrolled in this cross-sectional study. Plasma adiponectin was measured 2 days after index event by enzyme-linked immunosorbent assay. Aortic pulse wave velocity (PWV) was calculated by the transit-time method with the use of a velocity-encoded, phase-contrast cardiac magnetic resonance protocol. RESULTS Median plasma adiponectin concentration was 2385 ng/ml (interquartile range 1735-5403). Males had lower plasma adiponectin values than females and current smokers had lower values than non-smokers (all p<0.02). Adiponectin was significantly associated with PWV (r=0.505, p<0.001), age (r=0.437, p=0.002), and total cholesterol (r=0.468, p=0.001). Multiple linear regression analysis revealed adiponectin as a predictor of PWV independently of age, sex, smoking status, total cholesterol, and N-terminal pro-B-type natriuretic peptide (p=0.027). CONCLUSIONS Plasma adiponectin concentrations are strongly associated with aortic stiffness in patients after acute STEMI treated with primary PCI. Our data support a possible role for adiponectin as an independent risk marker for increased aortic stiffness in STEMI patients.
Collapse
|
34
|
Lindberg S, Jensen JS, Bjerre M, Pedersen SH, Frystyk J, Flyvbjerg A, Galatius S, Jeppesen J, Mogelvang R. Adiponectin, type 2 diabetes and cardiovascular risk. Eur J Prev Cardiol 2013; 22:276-83. [PMID: 24265290 DOI: 10.1177/2047487313514894] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND Adiponectin is viewed as an insulin-sensitizing hormone with anti-inflammatory effects. In accordance, plasma adiponectin is decreased in metabolic disorders including type 2 diabetes mellitus (T2DM). However, in spite of the apparently beneficially effects, recent data from large prospective studies have consistently linked high adiponectin levels with increased cardiovascular (CV) disease and mortality, thus questioning the positive view on adiponectin. Accordingly, we investigated the relationship between adiponectin, incident T2DM and subsequently CV events. METHODS We prospectively followed 5349 randomly selected men and women from the community, without T2DM or CV disease. Plasma adiponectin was measured at study entry. Median follow-up time was 8.5 years (IQR 8.0-9.1 years). During follow up, 136 participants developed T2DM. Following their diagnosis, 36 of the 136 participants experienced a CV event (myocardial infarction, ischaemic stroke, or CV death). RESULTS Participants with increasing adiponectin had reduced risk of developing T2DM (p < 0.001). After adjustment for confounding risk factors (including age, gender, body mass index, physical activity, alcohol consumption, blood glucose, HbA1c, blood pressure, lipids, high-sensitivity C-reactive protein, estimated glomerular filtration rate, and plasma N-terminal pro-brain natriuretic peptide, competing risk Cox-regression analysis identified adiponectin as an independent predictor of T2DM: hazard ratio (HR) for each doubling of adiponectin 0.55 (95% CI 0.41-0.74; p < 0.001). After development of T2DM, the risk of a CV event more than doubled. Increasing adiponectin (adjusted for the confounding risk factors mentioned) was associated with reduced risk of CV events: HR 0.34 (95% CI 0.16-0.72; p = 0.005) for each doubling in plasma adiponectin. CONCLUSIONS In conclusion, increasing plasma adiponectin is associated with decreased risk of T2DM and subsequently reduced risk of CV events.
Collapse
Affiliation(s)
- Søren Lindberg
- Bispebjerg University Hospital, Copenhagen, Denmark Gentofte University Hospital, Copenhagen, Denmark
| | - Jan Skov Jensen
- Bispebjerg University Hospital, Copenhagen, Denmark Gentofte University Hospital, Copenhagen, Denmark University of Copenhagen, Copenhagen, Denmark
| | - Mette Bjerre
- Aarhus University, Aarhus, Denmark Aarhus University Hospital, Aarhus, Denmark
| | | | - Jan Frystyk
- Aarhus University, Aarhus, Denmark Aarhus University Hospital, Aarhus, Denmark
| | - Allan Flyvbjerg
- Aarhus University, Aarhus, Denmark Aarhus University Hospital, Aarhus, Denmark
| | | | - Jørgen Jeppesen
- University of Copenhagen, Copenhagen, Denmark Glostrup Hospital, Copenhagen, Denmark
| | - Rasmus Mogelvang
- Bispebjerg University Hospital, Copenhagen, Denmark Gentofte University Hospital, Copenhagen, Denmark
| |
Collapse
|
35
|
Oliveira GBDF, França JÍD, Piegas LS. Serum adiponectin and cardiometabolic risk in patients with acute coronary syndromes. Arq Bras Cardiol 2013; 101:399-409. [PMID: 24029961 PMCID: PMC4081163 DOI: 10.5935/abc.20130186] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2012] [Accepted: 06/24/2013] [Indexed: 01/19/2023] Open
Abstract
Background The adipose tissue is considered not only a storable energy source, but mainly an
endocrine organ that secretes several cytokines. Adiponectin, a novel protein
similar to collagen, has been found to be an adipocyte-specific cytokine and a
promising cardiovascular risk marker. Objectives To evaluate the association between serum adiponectin levels and the risk for
cardiovascular events in patients with acute coronary syndromes (ACS), as well as
the correlations between adiponectin and metabolic, inflammatory, and myocardial
biomarkers. Methods We recruited 114 patients with ACS and a mean 1.13-year follow-up to measure
clinical outcomes. Clinical characteristics and biomarkers were compared according
to adiponectin quartiles. Cox proportional hazard regression models with Firth's
penalization were applied to assess the independent association between
adiponectin and the subsequent risk for both primary (composite of cardiovascular
death/non-fatal acute myocardial infarction (AMI)/non-fatal stroke) and co-primary
outcomes (composite of cardiovascular death/non-fatal AMI/non-fatal stroke/
rehospitalization requiring revascularization). Results There were significant direct correlations between adiponectin and age,
HDL-cholesterol, and B-type natriuretic peptide (BNP), and significant inverse
correlations between adiponectin and waist circumference, body weight, body mass
index, Homeostasis Model Assessment (HOMA) index, triglycerides, and insulin.
Adiponectin was associated with higher risk for primary and co-primary outcomes
(adjusted HR 1.08 and 1.07/increment of 1000; p = 0.01 and p = 0.02,
respectively). Conclusion In ACS patients, serum adiponectin was an independent predictor of cardiovascular
events. In addition to the anthropometric and metabolic correlations, there was a
significant direct correlation between adiponectin and BNP.
Collapse
Affiliation(s)
- Gustavo Bernardes de Figueiredo Oliveira
- Mailing Address: Gustavo Bernardes F. Oliveira, Av. Dr. Dante Pazzanese,
500. Unidade Coronária, 2.º andar, Unidade Hospitalar III. Postal Code
04012-909, São Paulo, SP - Brazil. E-mail:
,
| | | | | |
Collapse
|
36
|
Silbernagel G, Schöttker B, Appelbaum S, Scharnagl H, Kleber ME, Grammer TB, Ritsch A, Mons U, Holleczek B, Goliasch G, Niessner A, Boehm BO, Schnabel RB, Brenner H, Blankenberg S, Landmesser U, März W. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J 2013; 34:3563-71. [PMID: 24014391 DOI: 10.1093/eurheartj/eht343] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
AIMS High-density lipoprotein (HDL) cholesterol is a strong predictor of cardiovascular mortality. This work aimed to investigate whether the presence of coronary artery disease (CAD) impacts on its predictive value. METHODS AND RESULTS We studied 3141 participants (2191 males, 950 females) of the LUdwigshafen RIsk and Cardiovascular health (LURIC) study. They had a mean ± standard deviation age of 62.6 ± 10.6 years, body mass index of 27.5 ± 4.1 kg/m², and HDL cholesterol of 38.9 ± 10.8 mg/dL. The cohort consisted of 699 people without CAD, 1515 patients with stable CAD, and 927 patients with unstable CAD. The participants were prospectively followed for cardiovascular mortality over a median (inter-quartile range) period of 9.9 (8.7-10.7) years. A total of 590 participants died from cardiovascular diseases. High-density lipoprotein cholesterol by tertiles was inversely related to cardiovascular mortality in the entire cohort (P = 0.009). There was significant interaction between HDL cholesterol and CAD in predicting the outcome (P = 0.007). In stratified analyses, HDL cholesterol was strongly associated with cardiovascular mortality in people without CAD [3rd vs. 1st tertile: HR (95% CI) = 0.37 (0.18-0.74), P = 0.005], but not in patients with stable [3rd vs. 1st tertile: HR (95% CI) = 0.81 (0.61-1.09), P = 0.159] and unstable [3rd vs. 1st tertile: HR (95% CI) = 0.91 (0.59-1.41), P = 0.675] CAD. These results were replicated by analyses in 3413 participants of the AtheroGene cohort and 5738 participants of the ESTHER cohort, and by a meta-analysis comprising all three cohorts. CONCLUSION The inverse relationship of HDL cholesterol with cardiovascular mortality is weakened in patients with CAD. The usefulness of considering HDL cholesterol for cardiovascular risk stratification seems limited in such patients.
Collapse
Affiliation(s)
- Guenther Silbernagel
- Department of Angiology, Swiss Cardiovascular Center, Inselspital, University of Bern, Bern, Switzerland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Cox AJ, Lambird JE, An SS, Register TC, Langefeld CD, Carr JJ, Freedman BI, Bowden DW. Variants in adiponectin signaling pathway genes show little association with subclinical CVD in the diabetes heart study. Obesity (Silver Spring) 2013; 21:E456-62. [PMID: 23670978 DOI: 10.1002/oby.20184] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2012] [Accepted: 11/10/2012] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Understanding the interplay between adiposity, inflammation, and cardiovascular complications in type 2 diabetes mellitus (T2DM) remains a challenge. Signaling from adipocytes is considered important in this context. Adiponectin is the most abundant adipocytokine and has been associated with various measures of cardiovascular disease (CVD). This study examines the relationships between genetic variants in the adiponectin (ADIPOQ) and adiponectin-related signaling pathway genes and measures of subclinical CVD (vascular calcified plaque and carotid intima-media thickness), plasma lipids, and inflammation in T2DM. DESIGN AND METHODS Single-nucleotide polymorphisms (SNPs) in ADIPOQ (n = 45), SNPs tagging ADIPOR1 (n = 6), APIPOR2 (n = 8), APPL1 (n = 6) and known rare coding variants in KNG1 (n = 3) and LYZL1 (n = 3) were genotyped in 1220 European Americans from the family-based Diabetes Heart Study. Associations between SNPs and phenotypes of interest were assessed using a variance components analysis with adjustment for age, sex, T2DM-affected status, and body mass index. RESULTS There was minimal evidence of association between SNPs in the adiponectin signaling pathway genes and measures of calcified plaque; eight of the 71 SNPs showed evidence of association with subclinical CVD (P = 0.007-0.046) but not with other phenotypes examined. Nine additional SNPs were associated with at least one of the plasma lipid measures (P = 0.008-0.05). CONCLUSION Findings from this study do not support a significant role for variants in the adiponectin signaling pathway genes in contributing to risk for vascular calcification in T2DM. However, further understanding the interplay between adiposity, plasma lipids, and inflammation may prove important in the prediction and management of cardiovascular complications in T2DM.
Collapse
Affiliation(s)
- Amanda J Cox
- Center for Human Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Delhaye C, Kpogbemabou N, Modine T, Lemesle G, Staels B, Mahmoudi M, Tailleux A, Luc G, Bauters C, Lablanche JM, Sudre A. Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention. Int J Cardiol 2013; 168:4921-4. [PMID: 23953633 DOI: 10.1016/j.ijcard.2013.07.092] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2013] [Accepted: 07/08/2013] [Indexed: 11/30/2022]
Affiliation(s)
- Cédric Delhaye
- Hôpital Cardiologique, CHRU de Lille, boulevard Pr Leclercq, 59037 Lille cedex, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Affiliation(s)
- Eberhard Standl
- Munich Diabetes Research Group e.V. at Helmholtz Centre, Munich, Germany.
| | | | | |
Collapse
|
40
|
Marousi SG, Theodorou GL, Karakantza M, Zampakis P, Papathanasopoulos P, Ellul J. Acute post-stroke adiponectin in relation to stroke severity, progression and 6 month functional outcome. Neurol Res 2013; 32:841-4. [DOI: 10.1179/016164109x12581096796477] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
41
|
Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo Oh S. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 2013; 42:1029-39. [DOI: 10.1093/ije/dyt087] [Citation(s) in RCA: 92] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Schöttker B, Herder C, Rothenbacher D, Roden M, Kolb H, Müller H, Brenner H. Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. Diabetes Care 2013; 36:1703-11. [PMID: 23378623 PMCID: PMC3661844 DOI: 10.2337/dc12-1416] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Inflammatory processes contribute to both diabetes and cardiovascular risk. We wanted to investigate whether circulating concentrations of proinflammatory immune mediators and adiponectin in diabetic patients are associated with incident cardiovascular events. RESEARCH DESIGN AND METHODS In 1,038 participants with diabetes of the population-based ESTHER study, of whom 326 showed signs of renal dysfunction, Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for the association of increasing concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), IL-18, macrophage migration inhibitory factor (MIF), adiponectin, and leptin with cardiovascular events (myocardial infarction, stroke, or fatal cardiovascular event) during a follow-up period of 8 years. RESULTS During follow-up, 161 subjects with diabetes experienced a primary cardiovascular event. Proinflammatory markers were not associated with a higher risk for primary cardiovascular events in the total study population after adjustment for multiple confounders. However, IL-6 and MIF were associated with cardiovascular events in subjects with renal dysfunction (HR for the comparison of top vs. bottom tertile 1.98 [95% CI 1.12-3.52], P [trend] = 0.10 for IL-6; 1.48 [0.87-2.51], P [trend] = 0.04 for MIF). Adiponectin levels were associated with cardiovascular events in the total population (1.48 [1.01-2.21], P [trend] = 0.03), and the association was even more pronounced in the subgroup with renal dysfunction (1.97 [1.08-3.57], P [trend] = 0.02). CONCLUSIONS In particular, the absence of an association between CRP and a U-shaped association of adiponectin levels with incident cardiovascular events show that associations between circulating immune mediators and cardiovascular risk differ between diabetic patients and subjects of the general population.
Collapse
Affiliation(s)
- Ben Schöttker
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
| | | | | | | | | | | | | |
Collapse
|
43
|
Lindberg S, Mogelvang R, Pedersen SH, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Jensen JS. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol 2013; 111:1139-45. [PMID: 23375598 DOI: 10.1016/j.amjcard.2012.12.043] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Revised: 12/23/2012] [Accepted: 12/23/2012] [Indexed: 01/07/2023]
Abstract
Adiponectin exerts anti-inflammatory and antiatherogenic effects and appears to protect against arteriosclerosis. Accordingly, an association between low concentrations of plasma adiponectin and cardiovascular (CV) disease has been demonstrated in several studies. In contrast, elevated plasma adiponectin has been associated with increased mortality and an increasing number of major adverse CV events (MACE). Because of these conflicting results, the true role of adiponectin remains to be elucidated. In the Copenhagen City Heart Study, we prospectively followed up 5,624 randomly selected men and women from the community without CV disease. Plasma adiponectin was measured at the beginning of the study. The median follow-up time was 7.8 years (interquartile range 7.3 to 8.3). The end point was all-cause mortality (n = 801), and the combined end point was MACE, consisting of CV mortality or nonfatal myocardial infarction or ischemic stroke (n = 502). High adiponectin was inversely associated with an increasing number of traditional CV risk factors (p <0.0001). The geometric mean adiponectin concentrations were 10.0 mg/L (95% confidence interval [CI] 9.7 to 10.4) for persons with no CV risk factors present versus 8.1 mg/L (95% CI 7.8 to 8.4) for persons with 4 CV risk factors. After adjustment for confounding risk factors by Cox regression analysis, adiponectin remained an independent predictor of death and MACE. The hazard ratio for each increase in adiponectin of 5 mg/L for death and MACE was 1.20 (95% CI 1.14 to 1.27; p <0.0001) and 1.14 (95% CI 1.05-1.23; p <0.0001), respectively. In conclusion, an increasing number of risk factors for CV disease is associated with decreased plasma adiponectin. High plasma adiponectin independently predicted death and MACE in a large community-based population. These results have confirmed the dual expression indicated by previous studies.
Collapse
|
44
|
Hirata A, Kishida K, Nakatsuji H, Kobayashi H, Funahashi T, Shimomura I. High serum C1q-adiponectin/total adiponectin ratio correlates with coronary artery disease in Japanese type 2 diabetics. Metabolism 2013; 62:578-85. [PMID: 23174407 DOI: 10.1016/j.metabol.2012.10.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2012] [Revised: 10/18/2012] [Accepted: 10/18/2012] [Indexed: 11/23/2022]
Abstract
OBJECTIVE Adiponectin, an adipocyte-derived protein, has potential antiatherogenic properties. Low levels of serum total-adiponectin (Total-APN) correlate with diabetes and coronary artery disease (CAD). Adiponectin and C1q form a protein complex in blood, and serum C1q-binding adiponectin (C1q-APN) can be measured. We investigated the correlation between C1q-APN and CAD in patients with type 2 diabetes mellitus (T2DM). METHODS The study subjects were 107 outpatients with T2DM who underwent evaluation for CAD. Blood C1q, Total-APN, high-molecular weight-adiponectin (HMW-APN) and C1q-APN were measured by enzyme-linked immunosorbent assays. RESULTS Serum levels of C1q-APN/Total-APN ratio were higher in patients diagnosed with CAD (10.47±0.59, mean±SEM, n=54) than those without CAD (8.88±0.60, n=53, p=0.0482). Age- and sex-adjusted logistic regression analysis identified serum C1q-APN/Total-APN ratio and hypertension as significant and independent determinants of CAD. A high serum C1q-APN/Total-APN ratio was associated with 3.965-fold increase in CAD prevalence. CONCLUSIONS High serum C1q-APN/Total-APN ratio correlates with CAD in T2DM.
Collapse
Affiliation(s)
- Ayumu Hirata
- Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
| | | | | | | | | | | |
Collapse
|
45
|
Takahara M, Katakami N, Kishida K, Kaneto H, Funahashi T, Shimomura I, Matsunaga S, Kubo S, Fukamizu H, Otsuka A, Ichihara K, Nakamura T. Circulating Adiponectin Levels and their Associated Factors in Young Lean Healthy Japanese Women. J Atheroscler Thromb 2013; 20:57-64. [DOI: 10.5551/jat.14357] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
46
|
Chan KH, Lam KSL, Cheng OY, Kwan JSC, Ho PWL, Cheng KKY, Chung SK, Ho JWM, Guo VY, Xu A. Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity. PLoS One 2012; 7:e52354. [PMID: 23300647 PMCID: PMC3531475 DOI: 10.1371/journal.pone.0052354] [Citation(s) in RCA: 108] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2012] [Accepted: 11/12/2012] [Indexed: 12/19/2022] Open
Abstract
Beta-amyloid (Aβ ) neurotoxicity is important in Alzheimer’s disease (AD) pathogenesis. Aβ neurotoxicity causes oxidative stress, inflammation and mitochondrial damage resulting in neuronal degeneration and death. Oxidative stress, inflammation and mitochondrial failure are also pathophysiological mechanisms of type 2 diabetes (T2DM) which is characterized by insulin resistance. Interestingly, T2DM increases risk to develop AD which is associated with reduced neuronal insulin sensitivity (central insulin resistance). We studied the potential protective effect of adiponectin (an adipokine with insulin-sensitizing, anti-inflammatory and anti-oxidant properties) against Aβ neurotoxicity in human neuroblastoma cells (SH-SY5Y) transfected with the Swedish amyloid precursor protein (Sw-APP) mutant, which overproduced Aβ with abnormal intracellular Aβ accumulation. Cytotoxicity was measured by assay for lactate dehydrogenase (LDH) released upon cell death and lysis. Our results revealed that Sw-APP transfected SH-SY5Y cells expressed both adiponectin receptor 1 and 2, and had increased AMP-activated protein kinase (AMPK) activation and enhanced nuclear factor-kappa B (NF-κB) activation compared to control empty-vector transfected SH-SY5Y cells. Importantly, adiponectin at physiological concentration of 10 µg/ml protected Sw-APP transfected SH-SY5Y cells against cytotoxicity under oxidative stress induced by hydrogen peroxide. This neuroprotective action of adiponectin against Aβ neurotoxicity-induced cytotoxicity under oxidative stress involved 1) AMPK activation mediated via the endosomal adaptor protein APPL1 (adaptor protein with phosphotyrosine binding, pleckstrin homology domains and leucine zipper motif) and possibly 2) suppression of NF-κB activation. This raises the possibility of novel therapies for AD such as adiponectin receptor agonists.
Collapse
Affiliation(s)
- Koon-Ho Chan
- University Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Special Administrative Region, China.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Li Q, Lu Y, Sun L, Yan J, Yan X, Fang L, Li M, Fan Z. Plasma adiponectin levels in relation to prognosis in patients with angiographic coronary artery disease. Metabolism 2012; 61:1803-8. [PMID: 22789446 DOI: 10.1016/j.metabol.2012.06.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2011] [Revised: 06/01/2012] [Accepted: 06/01/2012] [Indexed: 01/17/2023]
Abstract
OBJECTIVE The objective was to study the associations between adiponectin levels and cardiovascular adverse clinical outcomes in patients with angiographic coronary artery disease (CAD) within the Han Chinese population in Beijing. MATERIALS/METHODS A total of 449 hospitalized patients with angiographic CAD who were Han Chinese in Beijing participated in the study. Plasma adiponectin levels were examined from blood samples using a type of unique enzyme-linked immunosorbent assay that was developed by our laboratory. All of the patients' clinical data, including previously identified cardiovascular risk factors, creatinine clearance and left ventricle ejection fraction, were recorded after admission, and patients were followed up for 19±8 months. The primary end-point was marked by the occurrence of major adverse cardiovascular events (MACE), which included death, targeted vascular revascularization, acute coronary syndrome, heart failure, and transient ischemic attack (TIA) / stroke. RESULTS A total of 109 cases of MACE occurred: 15 cases of death, 66 cases of acute coronary syndrome, 4 cases of TIA/stroke, 6 cases of targeted vessel revascularization, and 18 cases of heart failure. Among all the patients, 173 were assigned to the high adiponectin group and 276 were assigned to the low adiponectin group according to their baseline plasma adiponectin levels. The incidence of MACE was significantly higher in the low adiponectin group (P=.037). In a multivariate Cox regression analysis for adiponectin levels, previously documented risk factors, coronary artery stenosis scores, and low adiponectin levels were indicated as independent predictors of MACE in patients with CAD (RR 1.75; 95% CI, 1.066-2.865; P=.027). Further adjustment for hsCRP, Ccr, LVEF, fasting glucose and lipid profile did not attenuate this association (RR=2.36; 95% CI 1.338-4.167; P=.003). The relative risk for low adiponectin levels after additional adjustment for the coronary score was 2.42 (95% CI 1.367-4.279; P=.002). The Kaplan-Meier survival analysis curve suggested that patients with lower adiponectin concentrations had a decreased event-free survival ratio (log-rank χ(2) =4.592, P=.032). CONCLUSIONS The results indicate a potential association between plasma adiponectin levels and cardiovascular prognosis in patients with CAD.
Collapse
Affiliation(s)
- Quan Li
- Division of Cardiology, Department of Medicine, Peking Union Medical College Hospital, PUMC, Chinese Academy of Medical Sciences, Beijing 100730, China
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Lee CH, Hau WKT, Tai BC, Chan MY, Saw B, Phua QH, Low AF, Yeo TC, Richards AM, Tan HC. Adiponectin profile in Asian patients undergoing coronary revascularization and its association with plaque vulnerability: IDEAS-ADIPO study. Obesity (Silver Spring) 2012; 20:2451-7. [PMID: 22510959 DOI: 10.1038/oby.2012.92] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Despite potent insulin-sensitizing, anti-inflammatory, and antiatherogenic effects in animal studies, the relationship between serum adiponectin level and coronary artery disease in patients remains unclear. We determined the adiponectin profile in a cohort of multiethnic Asian patients with coronary artery disease, and the association between serum adiponectin level and culprit lesion necrotic core (NC) content. Ninety-four Asian patients (BMI, 25.3 ± 3.7 kg/m(2)) undergoing percutaneous coronary intervention were recruited. The serum adiponectin level was measured (n = 94), and the baseline virtual histology intravascular ultrasound examination was analyzed (n = 88). The median level of adiponectin was 3.7 µg/ml (interquartile range, 2.8-4.5 µg/ml). The serum adiponectin level was below 10 µg/ml in 90 patients (95.7%) and below 6 µg/ml in 80 patients (85.1%). There was a significant association between ethnicity and serum adiponectin level (P = 0.048). The median adiponectin level was highest among the Chinese, followed by the Malay and the Indians. Serum adiponectin levels were positively associated with culprit lesion NC content. A 1-µg/ml increase in log adiponectin was associated with a 3.04% (95% confidence interval: 0.33-5.44) increase in culprit lesion NC content. This association remains significant after adjusting for age, sex, ethnicity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and procedural indication. We found a low serum level of adiponectin in Asian patients and a significant ethnic effect on serum adiponectin level. Increased serum adiponectin levels were independently associated with increased culprit lesion NC burden, suggesting a role for adiponectin in modulating coronary plaque vulnerability.
Collapse
Affiliation(s)
- Chi-Hang Lee
- Department of Medicine, National University of Singapore, Singapore. )
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Baseline epicardial adipose tissue adiponectin levels predict cardiovascular outcomes: A long-term follow-up study. Cytokine 2012; 60:674-80. [DOI: 10.1016/j.cyto.2012.08.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2012] [Revised: 08/07/2012] [Accepted: 08/10/2012] [Indexed: 01/04/2023]
|
50
|
Arterial stiffness is associated with increased monocyte expression of adiponectin receptor mRNA and protein in patients with coronary artery disease. Am J Hypertens 2012; 25:746-55. [PMID: 22534793 DOI: 10.1038/ajh.2012.42] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Arterial stiffness and carotid intima-media thickness (IMT) constitute validated cardiovascular prognostic markers. Adiponectin and its receptors 1 (AdipoR1) and 2 (AdipoR2) are involved in coronary artery disease (CAD). We investigated whether AdipoR1 and R2 mRNA and protein expression are associated with arterial stiffness, IMT and extent of coronary atherosclerosis. METHODS We studied 71 patients (61 men, 10 women) with angiographically proven CAD. We measured: (i) monocyte expression of AdipoR1 and AdipoR2 mRNA (quantitative real-time PCR) and protein expression (flow cytometry) (iii) adiponectin, metalloproteinase-9 (MMP-9) and C-reactive protein (CRP) blood levels, (iv) carotid-femoral artery pulse wave velocity (PWV) and carotid IMT. RESULTS Patients with multi-vessel CAD had higher AdipoR1 and AdipoR2 mRNA than those with single-vessel (P < 0.05). PWV was associated with AdipoR1 mRNA (r = 0.474), AdipoR1 protein (r = 0.228), AdipoR2 mRNA (r = 0.716), AdipoR2-protein (r = 0.261), adiponectin (r = 0.236), and MMP-9 (r = 0.350) (P < 0.05, for all correlations). After adjustment for age, sex, waist-hip ratio, and mean blood pressure both AdipoR1 and AdipoR2 mRNA remained independent determinants of PWV (R(2) = 0.35 and R(2) = 0.57, P < 0.05). IMT was also associated with AdipoR2 mRNA, AdipoR2 protein, and MMP-9 (P < 0.05). Increased expression of ADR2 mRNA significantly related to MMP-9 (r = 0.210), and CRP (r = 0.531) (P < 0.05). CONCLUSION Increased mRNA and protein expression of adiponectin receptors is related with increased aortic stiffness, coronary and peripheral atherosclerosis in patients with CAD. The interrelation of AdipoR2 with inflammatory markers, PWV and IMT suggests a compensatory increase of these receptors to counteract the excess inflammatory and atherogenic process in CAD. Thus, adiponectin receptors may provide a potential therapeutic target of agents activating their beneficial action.American Journal of Hypertension 2012; doi:10.1038/ajh.2012.42.
Collapse
|